<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><front><journal-meta><journal-id journal-id-type="nlm-ta">Trials</journal-id><journal-id journal-id-type="iso-abbrev">Trials</journal-id><journal-title-group><journal-title>Trials</journal-title></journal-title-group><issn pub-type="epub">1745-6215</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24266960</article-id><article-id pub-id-type="pmc">4222827</article-id><article-id pub-id-type="publisher-id">1745-6215-14-401</article-id><article-id pub-id-type="doi">10.1186/1745-6215-14-401</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Prevention of Decline in Cognition after Stroke Trial (PODCAST): a study protocol for a factorial randomised controlled trial of intensive versus guideline lowering of blood pressure and lipids</article-title></title-group><contrib-group><contrib contrib-type="author" id="A1"><name><surname>Blackburn</surname><given-names>Daniel J</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>d.blackburn@sheffield.ac.uk</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Krishnan</surname><given-names>Kailash</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>Kailash.Krishnan@nottingham.ac.uk</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Fox</surname><given-names>Lydia</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>Lydia.Fox@nottingham.ac.uk</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Ballard</surname><given-names>Clive</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>clive.ballard@kcl.ac.uk</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Burns</surname><given-names>Alistair</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>alistair.burns@manchester.ac.uk</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Ford</surname><given-names>Gary A</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>gary.ford@ncl.ac.uk</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Mant</surname><given-names>Jonathan</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>jm677@medschl.cam.ac.uk</email></contrib><contrib contrib-type="author" id="A8"><name><surname>Passmore</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="I7">7</xref><email>p.passmore@qub.ac.uk</email></contrib><contrib contrib-type="author" id="A9"><name><surname>Pocock</surname><given-names>Stuart</given-names></name><xref ref-type="aff" rid="I8">8</xref><email>stuart.pocock@lshtm.ac.uk</email></contrib><contrib contrib-type="author" id="A10"><name><surname>Reckless</surname><given-names>John</given-names></name><xref ref-type="aff" rid="I9">9</xref><email>mpsjdr@bath.ac.uk</email></contrib><contrib contrib-type="author" id="A11"><name><surname>Sprigg</surname><given-names>Nikola</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>nikola.sprigg@nottingham.ac.uk</email></contrib><contrib contrib-type="author" id="A12"><name><surname>Stewart</surname><given-names>Rob</given-names></name><xref ref-type="aff" rid="I10">10</xref><email>r.stewart@iop.kcl.ac.uk</email></contrib><contrib contrib-type="author" id="A13"><name><surname>Wardlaw</surname><given-names>Joanna</given-names></name><xref ref-type="aff" rid="I11">11</xref><email>Joanna.Wardlaw@ed.ac.uk</email></contrib><contrib contrib-type="author" corresp="yes" id="A14"><name><surname>Bath</surname><given-names>Philip MW</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>philip.bath@nottingham.ac.uk</email></contrib></contrib-group><aff id="I1"><label>1</label>Sheffield Institute for Translational Neuroscience, University of Sheffield, 385A Glossop Road, Sheffield S10 2HQ, UK</aff><aff id="I2"><label>2</label>Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, City Hospital campus, Nottingham NG5 1PB, UK</aff><aff id="I3"><label>3</label>Wolfson Centre for Age-Related Diseases, Wolfson Wing, Hodgkin Building, King’s College London, Guy’s Campus, London SE1 1UL, UK</aff><aff id="I4"><label>4</label>Faculty of Medical and Human Sciences, Institute of Brain, Behavior and Mental Health, University of Manchester, Grafton Street, Manchester M13 9NT, UK</aff><aff id="I5"><label>5</label>Level 6, Leazes Wing, Royal Victoria Infirmary, Newcastle NE14 LP5, UK</aff><aff id="I6"><label>6</label>General Practice &amp; Primary Care Research Unit, University of Cambridge, Addenbrooke’s Hospital, Forvie Site, Cambridge CB2 0SR, UK</aff><aff id="I7"><label>7</label>Institute of Clinical Sciences, Queens University, Belfast, Royal Victoria Hospital, Block B, Belfast BT12 6BA, UK</aff><aff id="I8"><label>8</label>Department of Medical Statistics, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK</aff><aff id="I9"><label>9</label>Department of Endocrinology, Royal United Hospital, Combe Park, Bath BA1 3NG, UK</aff><aff id="I10"><label>10</label>Section of Epidemiology (Box 60), Institute of Psychiatry (King's College London), De Crespigny Park, London SE5 8AF, UK</aff><aff id="I11"><label>11</label>Division of Clinical Neurosciences, Western General Hospital, Crewe Rd, Edinburgh EH4 2XU, UK</aff><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>22</day><month>11</month><year>2013</year></pub-date><volume>14</volume><fpage>401</fpage><lpage>401</lpage><history><date date-type="received"><day>24</day><month>7</month><year>2013</year></date><date date-type="accepted"><day>28</day><month>10</month><year>2013</year></date></history><permissions><copyright-statement>Copyright © 2013 Blackburn et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Blackburn et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.trialsjournal.com/content/14/1/401"></self-uri><abstract><sec><title><offsets xml_i="6805" xml_f="6815" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="6826" xml_f="7063" txt_i="22" txt_f="259">Stroke is a common cause of cognitive impairment and dementia. However, effective strategies for reducing the risk of post-stroke dementia remain undefined. Potential strategies include intensive lowering of blood pressure and/or lipids.</offsets></p></sec><sec><title><offsets xml_i="7085" xml_f="7099" txt_i="261" txt_f="275">Methods/Design</offsets></title><p><offsets xml_i="7110" xml_f="7256" txt_i="276" txt_f="422">Design: multi-centre prospective randomised open-label blinded-endpoint controlled partial-factorial phase IV trial in secondary and primary care.</offsets></p><p><offsets xml_i="7263" xml_f="7419" txt_i="423" txt_f="579">Participants: 100 participants from 30 UK Stroke Research Network sites who are post- ischemic stroke or intracerebral haemorrhage by three to seven months.</offsets></p><p><offsets xml_i="7426" xml_f="7566" txt_i="580" txt_f="714">Interventions - all patients (1:1): intensive versus guideline blood pressure lowering (target systolic &lt; 125 mmHg versus &lt; 140 mmHg).</offsets></p><p><offsets xml_i="7573" xml_f="7744" txt_i="715" txt_f="880">Interventions - ischemic stroke (1:1): intensive versus guideline lipid lowering (target low density lipoprotein-cholesterol (LDL-c) &lt; 1.4 mmol/l versus &lt; 3 mmol/l).</offsets></p><p><offsets xml_i="7751" xml_f="8042" txt_i="881" txt_f="1172">Hypotheses: does ‘intensive’ blood pressure lowering therapy and/or ‘intensive’ lipid control reduce cognitive decline and dementia in people with ischemic stroke; and does ‘intensive’ blood pressure lowering therapy reduce cognitive decline and dementia in patients with hemorrhagic stroke.</offsets></p><p><offsets xml_i="8049" xml_f="8110" txt_i="1173" txt_f="1234">Primary outcome: Addenbrooke’s Cognitive Examination-Revised.</offsets></p><p><offsets xml_i="8117" xml_f="8525" txt_i="1235" txt_f="1637">Secondary outcomes: feasibility of recruitment and retention of participants, tolerability and safety of the interventions, achieving and maintaining the blood pressure and lipid targets, maintaining differences in systolic blood pressure (&gt; 10 mmHg) and low density lipoprotein-cholesterol (&gt; 1 mmol/l) between the treatment groups, and performing clinic and telephone follow-up of cognition measures.</offsets></p><p><offsets xml_i="8532" xml_f="8607" txt_i="1638" txt_f="1713">Randomisation: using stratification, minimization and simple randomization.</offsets></p><p><offsets xml_i="8614" xml_f="8851" txt_i="1714" txt_f="1951">Blinding: participants receive open-label management. Cognition is assessed both unblinded (in clinic) and blinded (by telephone) to treatment. Adjudication of events (dementia, vascular, serious adverse events) is blinded to management.</offsets></p></sec><sec><title><offsets xml_i="8873" xml_f="8883" txt_i="1953" txt_f="1963">Discussion</offsets></title><p><offsets xml_i="8894" xml_f="9032" txt_i="1964" txt_f="2102">The PODCAST trial is ongoing with 78 patients recruited to date from 22 sites. Outcomes of cognitive impairment and dementia are accruing.</offsets></p></sec><sec><title><offsets xml_i="9054" xml_f="9072" txt_i="2104" txt_f="2122">Trial registration</offsets></title><p><ext-link ext-link-type="uri" xlink:href="http://www.controlled-trials.com/ISRCTN85562386"><offsets xml_i="9174" xml_f="9188" txt_i="2123" txt_f="2137">ISRCTN85562386</offsets></ext-link></p></sec></abstract><kwd-group><kwd>Stroke</kwd><kwd>Post-stroke cognitive impairment</kwd><kwd>Post-stroke dementia</kwd><kwd>Blood pressure lowering</kwd><kwd>Lipid lowering</kwd></kwd-group></article-meta></front><body><sec><title><offsets xml_i="9434" xml_f="9444" txt_i="2146" txt_f="2156">Background</offsets></title><sec><title><offsets xml_i="9464" xml_f="9496" txt_i="2157" txt_f="2189">Post-stroke cognitive impairment</offsets></title><p><offsets xml_i="9507" xml_f="9576" txt_i="2190" txt_f="2259">Post-stroke cognitive impairment is common, ranging from 17 to 92%, [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="9607" xml_f="9608" txt_i="2259" txt_f="2260">1</offsets></xref><offsets xml_i="9615" xml_f="9616" txt_i="2260" txt_f="2261">,</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="9647" xml_f="9648" txt_i="2261" txt_f="2262">2</offsets></xref><offsets xml_i="9655" xml_f="9731" txt_i="2262" txt_f="2338">] and is associated with increased mortality and decreased quality of life [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="9762" xml_f="9763" txt_i="2338" txt_f="2339">3</offsets></xref><offsets xml_i="9770" xml_f="9771" txt_i="2339" txt_f="2340">-</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="9802" xml_f="9803" txt_i="2340" txt_f="2341">5</offsets></xref><offsets xml_i="9810" xml_f="9895" txt_i="2341" txt_f="2426">]. Nevertheless, cognitive impairment may improve or deteriorate following a stroke [</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="9926" xml_f="9927" txt_i="2426" txt_f="2427">6</offsets></xref><offsets xml_i="9934" xml_f="10056" txt_i="2427" txt_f="2549">]. Risk factors for cognitive decline include executive dysfunction, white matter hyperintensities (WMH), ApoE e4 status [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="10087" xml_f="10088" txt_i="2549" txt_f="2550">7</offsets></xref><offsets xml_i="10095" xml_f="10133" txt_i="2550" txt_f="2588">] and atrophy of crucial brain areas [</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="10164" xml_f="10165" txt_i="2588" txt_f="2589">8</offsets></xref><offsets xml_i="10172" xml_f="10174" txt_i="2589" txt_f="2591">].</offsets></p><p><offsets xml_i="10181" xml_f="10454" txt_i="2592" txt_f="2865">Many potential interventions for preventing cognitive decline have been proposed, including blood pressure (BP) and lipid lowering, antiplatelet agents, anti-oxidant vitamins, and cholinesterase inhibitors. Of these, lowering BP and blood lipids are priorities for testing.</offsets></p></sec><sec><title><offsets xml_i="10476" xml_f="10499" txt_i="2867" txt_f="2890">Blood pressure lowering</offsets></title><p><offsets xml_i="10510" xml_f="10786" txt_i="2891" txt_f="3167">Lowering BP post-stroke is highly effective in reducing recurrent and other vascular events, as shown in individual trials (such as Post-stroke Antihypertensive Treatment Study (PATS, n = 5,665) and Perindopril protection against recurrent stroke study (PROGRESS, n = 6,105) [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="10817" xml_f="10818" txt_i="3167" txt_f="3168">9</offsets></xref><offsets xml_i="10825" xml_f="10826" txt_i="3168" txt_f="3169">,</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="10858" xml_f="10860" txt_i="3169" txt_f="3171">10</offsets></xref><offsets xml_i="10867" xml_f="10899" txt_i="3171" txt_f="3203">]) and a meta-analysis of them [</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="10931" xml_f="10933" txt_i="3203" txt_f="3205">11</offsets></xref><offsets xml_i="10940" xml_f="11018" txt_i="3205" txt_f="3283">]. However, the effect on cognitive function of lowering BP is far less clear.</offsets></p><p><offsets xml_i="11025" xml_f="11239" txt_i="3284" txt_f="3498">Longitudinal studies have shown that premorbid high systolic blood pressure (SBP) and diastolic blood pressure (DBP) are associated with WMH and an increased risk of Alzheimer’s disease (AD) and vascular dementia [</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="11271" xml_f="11273" txt_i="3498" txt_f="3500">12</offsets></xref><offsets xml_i="11280" xml_f="11281" txt_i="3500" txt_f="3501">-</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="11313" xml_f="11315" txt_i="3501" txt_f="3503">14</offsets></xref><offsets xml_i="11322" xml_f="11565" txt_i="3503" txt_f="3746">]. Although no trials have been expressly designed to test the effect of lowering BP on subsequent cognition post-stroke, several have included cognition as a secondary outcome measure. Whilst potential benefit was seen in the PROGRESS study [</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="11597" xml_f="11599" txt_i="3746" txt_f="3748">15</offsets></xref><offsets xml_i="11606" xml_f="11719" txt_i="3748" txt_f="3861">], none was found in the Prevention Regimen for Effectively Avoiding Second Strokes trial (PRoFESS, n = 20,332) [</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="11751" xml_f="11753" txt_i="3861" txt_f="3863">16</offsets></xref><offsets xml_i="11760" xml_f="11986" txt_i="3863" txt_f="4089">]. Similar mixed results have been seen in trials of BP lowering in non-stroke populations, for example, the Hypertension in the Very Elderly Trial (HYVET, n = 3,845) and Systolic Hypertension in Europe (Syst-Eur, n = 4,695) [</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="12018" xml_f="12020" txt_i="4089" txt_f="4091">17</offsets></xref><offsets xml_i="12027" xml_f="12028" txt_i="4091" txt_f="4092">,</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="12060" xml_f="12062" txt_i="4092" txt_f="4094">18</offsets></xref><offsets xml_i="12069" xml_f="12224" txt_i="4094" txt_f="4249">]. In a meta-analysis involving both stroke and non-stroke patients, lowering BP was associated with less cognitive decline, and a trend to less dementia [</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="12256" xml_f="12258" txt_i="4249" txt_f="4251">19</offsets></xref><offsets xml_i="12265" xml_f="12380" txt_i="4251" txt_f="4366">]; meta-regression suggested that the degree of reduction in cognition was related to the magnitude of BP lowering.</offsets></p><p><offsets xml_i="12387" xml_f="12558" txt_i="4367" txt_f="4538">The Secondary Prevention of Small Subcortical Strokes (SPS3, n = 3,020) factorial trial of intensive versus guideline BP lowering, and aspirin/clopidogrel versus aspirin [</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="12590" xml_f="12592" txt_i="4538" txt_f="4540">20</offsets></xref><offsets xml_i="12599" xml_f="12715" txt_i="4540" txt_f="4656">], in patients with MRI-proven lacunar stroke will be presenting the effects of intensive BP lowering on cognition [</offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="12747" xml_f="12749" txt_i="4656" txt_f="4658">21</offsets></xref><offsets xml_i="12756" xml_f="12967" txt_i="4658" txt_f="4869">] in 2014. The ongoing PRESsure in established cERebral small VEssel disease (PRESERVE, n = 422) trial is also investigating the effect of lowering BP in patients with established cerebral small vessel disease (</offsets><ext-link ext-link-type="uri" xlink:href="http://www.controlled-trials.com/ISRCTN37694103"><offsets xml_i="13058" xml_f="13105" txt_i="4869" txt_f="4916">http://www.controlled-trials.com/ISRCTN37694103</offsets></ext-link><offsets xml_i="13116" xml_f="13143" txt_i="4916" txt_f="4943">, downloaded 20 June 2013).</offsets></p></sec><sec><title><offsets xml_i="13165" xml_f="13179" txt_i="4945" txt_f="4959">Lipid lowering</offsets></title><p><offsets xml_i="13190" xml_f="13584" txt_i="4960" txt_f="5354">The majority of information on lipid lowering and cognition relates to statins rather than older interventions such as fibrates, nicotinic acid derivatives or resins. Statins have pleiotropic effects that include lowering cholesterol (specifically low density lipoprotein-cholesterol (LDL-c)) and reducing platelet activity, inflammation and the release of cytokines and acute phase reactants [</offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="13616" xml_f="13618" txt_i="5354" txt_f="5356">22</offsets></xref><offsets xml_i="13625" xml_f="13626" txt_i="5356" txt_f="5357">,</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="13658" xml_f="13660" txt_i="5357" txt_f="5359">23</offsets></xref><offsets xml_i="13667" xml_f="13811" txt_i="5359" txt_f="5503">]. These effects might limit the progression of Alzheimer’s pathology from an asymptomatic state to symptomatic, or deterioration after stroke [</offsets><xref ref-type="bibr" rid="B24"><offsets xml_i="13843" xml_f="13845" txt_i="5503" txt_f="5505">24</offsets></xref><offsets xml_i="13852" xml_f="13990" txt_i="5505" txt_f="5643">]. Although statins are one of the most widely prescribed drugs with clear health benefits in reducing vascular events, including stroke [</offsets><xref ref-type="bibr" rid="B25"><offsets xml_i="14022" xml_f="14024" txt_i="5643" txt_f="5645">25</offsets></xref><offsets xml_i="14031" xml_f="14032" txt_i="5645" txt_f="5646">-</offsets><xref ref-type="bibr" rid="B27"><offsets xml_i="14064" xml_f="14066" txt_i="5646" txt_f="5648">27</offsets></xref><offsets xml_i="14073" xml_f="14243" txt_i="5648" txt_f="5818">], and death, there is little direct evidence that lipid lowering prevents cognitive decline in either people with normal cognition or patients with cognitive impairment.</offsets></p><p><offsets xml_i="14250" xml_f="14388" txt_i="5819" txt_f="5957">The Heart Protection Study (HPS, n = 20,536) found significant reductions in coronary artery and cerebrovascular events with simvastatin [</offsets><xref ref-type="bibr" rid="B28"><offsets xml_i="14420" xml_f="14422" txt_i="5957" txt_f="5959">28</offsets></xref><offsets xml_i="14429" xml_f="14991" txt_i="5959" txt_f="6521">] but there was no difference in cognition on treatment (baseline measures were not taken so change could not be assessed), assessed using the Telephone Interview for Cognitive Status (TICS), even when sub-groups of older patients, and those with prior stroke, were analysed. Similarly, the Pravastatin in elderly individuals at risk of vascular disease (PROSPER, n = 5,804) trial in people aged 70 to 82 with vascular risk factors reported no effect on cognition (measured using Mini Mental State Examination (MMSE), Stroop and a series of psychometric tests) [</offsets><xref ref-type="bibr" rid="B29"><offsets xml_i="15023" xml_f="15025" txt_i="6521" txt_f="6523">29</offsets></xref><offsets xml_i="15032" xml_f="15208" txt_i="6523" txt_f="6699">]. A meta-analysis of three trials found a non-significant trend to higher MMSE scores in patients with AD who were randomised to statin treatment (atorvastatin, simvastatin) [</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="15240" xml_f="15242" txt_i="6699" txt_f="6701">19</offsets></xref><offsets xml_i="15249" xml_f="15251" txt_i="6701" txt_f="6703">].</offsets></p><p><offsets xml_i="15258" xml_f="15527" txt_i="6704" txt_f="6973">Thus, there is no clear evidence that statins reduce the risk of cognitive decline or dementia but this has not been formally examined in a high-risk population. In contrast, there has been some concern that statins are associated with reversible cognitive impairment [</offsets><xref ref-type="bibr" rid="B30"><offsets xml_i="15559" xml_f="15561" txt_i="6973" txt_f="6975">30</offsets></xref><offsets xml_i="15568" xml_f="15665" txt_i="6975" txt_f="7072">], either due to an idiosyncratic response to statins or an underlying mitochondrial dysfunction.</offsets></p></sec></sec><sec><title><offsets xml_i="15693" xml_f="15707" txt_i="7075" txt_f="7089">Methods/design</offsets></title><sec><title><offsets xml_i="15727" xml_f="15734" txt_i="7090" txt_f="7097">Purpose</offsets></title><p><offsets xml_i="15745" xml_f="15825" txt_i="7098" txt_f="7178">To develop interventions to prevent cognitive decline and dementia after stroke.</offsets></p></sec><sec><title><offsets xml_i="15847" xml_f="15865" txt_i="7180" txt_f="7198">Primary objectives</offsets></title><sec><title><offsets xml_i="15885" xml_f="15899" txt_i="7199" txt_f="7213">Start-up phase</offsets></title><p><offsets xml_i="15910" xml_f="16037" txt_i="7214" txt_f="7341">To determine the feasibility of recruiting and retaining patients, and identify any barriers to achieving BP and lipid targets.</offsets></p></sec><sec><title><offsets xml_i="16059" xml_f="16069" txt_i="7343" txt_f="7353">Main phase</offsets></title><p><offsets xml_i="16080" xml_f="16236" txt_i="7354" txt_f="7510">To determine if ‘intensive’ blood pressure lowering therapy, and/or ‘intensive’ lipid lowering therapy, after stroke reduces cognitive decline and dementia.</offsets></p></sec></sec><sec><title><offsets xml_i="16264" xml_f="16284" txt_i="7513" txt_f="7533">Secondary objectives</offsets></title><sec><title><offsets xml_i="16304" xml_f="16318" txt_i="7534" txt_f="7548">Start-up phase</offsets></title><p><offsets xml_i="16329" xml_f="16567" txt_i="7549" txt_f="7787">To determine the feasibility of recruiting and retaining sites, reaching and maintaining target BP and lipid levels, performing cognitive assessment in clinic and by telephone, and the tolerability and safety of the management strategies.</offsets></p></sec><sec><title><offsets xml_i="16589" xml_f="16599" txt_i="7789" txt_f="7799">Main phase</offsets></title><p><offsets xml_i="16610" xml_f="16830" txt_i="7800" txt_f="8020">To determine if ‘intensive’ blood pressure lowering therapy, and/or ‘intensive’ lipid lowering therapy, after stroke reduces poor quality of life, poor function, depression, stroke recurrence, vascular events, and death.</offsets></p></sec></sec><sec><title><offsets xml_i="16858" xml_f="16862" txt_i="8023" txt_f="8027">Aims</offsets></title><sec><title><offsets xml_i="16882" xml_f="16896" txt_i="8028" txt_f="8042">Start-up phase</offsets></title><p><offsets xml_i="16907" xml_f="16929" txt_i="8043" txt_f="8065">This is assessing the:</offsets></p><p><offsets xml_i="16936" xml_f="16968" txt_i="8066" txt_f="8098">•Ability to deliver the protocol</offsets></p><p><offsets xml_i="16975" xml_f="17014" txt_i="8099" txt_f="8138">•Ability to recruit 30 recruiting sites</offsets></p><p><offsets xml_i="17021" xml_f="17068" txt_i="8139" txt_f="8186">•Ability to recruit and retain 600 participants</offsets></p><p><offsets xml_i="17075" xml_f="17222" txt_i="8187" txt_f="8334">•Ability to achieve and maintain differences in systolic BP ≥ 10 mmHg and LDL-c ≥ 1 mmol/l between the ‘intensive’ and ‘guideline’ treatment groups</offsets></p><p><offsets xml_i="17229" xml_f="17299" txt_i="8335" txt_f="8405">•Ability to perform clinic and telephone follow-up of outcome measures</offsets></p><p><offsets xml_i="17306" xml_f="17420" txt_i="8406" txt_f="8520">•Sensitivity of the Addenbrooke’s Cognitive Examination-R (ACE-R) and other cognitive measures to change over time</offsets></p><p><offsets xml_i="17427" xml_f="17471" txt_i="8521" txt_f="8565">•Tolerability and safety of the intervention</offsets></p></sec><sec><title><offsets xml_i="17493" xml_f="17503" txt_i="8567" txt_f="8577">Main phase</offsets></title><p><offsets xml_i="17514" xml_f="17877" txt_i="8578" txt_f="8941">A main phase was planned to assess the safety and efficacy of intensive versus guideline BP and lipid management in preventing cognitive decline. A total of 3,400 patients (start-up 600, main 2,800) post-stroke were planned. However, the main phase was cancelled 24 months into the pilot phase because of a failure to achieve a sufficiently high recruitment rate.</offsets></p></sec></sec><sec><title><offsets xml_i="17905" xml_f="17911" txt_i="8944" txt_f="8950">Design</offsets></title><p><offsets xml_i="17922" xml_f="18728" txt_i="8951" txt_f="9757">PODCAST is a multi-centre prospective randomised open-label blinded-endpoint controlled partial-factorial phase IV trial. The study is conducted according to the principles of the Declaration of Helsinki and ‘International Conference on Harmonisation of Good Clinical Practice’. Study approval by national (UK, approval 09/H0403/71, date 12 November 2009) and local research ethics committees (all centres) has been obtained. As a management trial, the study does not fall under the remit of the UK Medicines and Healthcare Products Regulatory Authority (as confirmed by them). The management of personal data adheres to the UK Data Protection Act 1998. The UK National Institutes Health Research Stroke Research Network supports the trial through screening and recruitment of patients (23 September 2009).</offsets></p></sec><sec><title><offsets xml_i="18750" xml_f="18768" txt_i="9759" txt_f="9777">Patient population</offsets></title><p><offsets xml_i="18779" xml_f="19177" txt_i="9778" txt_f="10176">Participants are recruited from hospital-based stroke services, and are consented for a face-to face assessment of cognition (telephone-Mini Mental Status Examination, t-MMSE) and function (modified Rankin Scale, mRS) at 8 to 26 weeks after the stroke. If the participant is eligible and interested after the initial assessment, fasting lipids, glucose, urea and electrolytes, and HbA1c are tested.</offsets></p><sec><title><offsets xml_i="19193" xml_f="19211" txt_i="10177" txt_f="10195">Inclusion criteria</offsets></title><p><offsets xml_i="19222" xml_f="19322" txt_i="10196" txt_f="10287">1. Age &gt; 70 years and t-MMSE &gt; 16 (maximum score 22); or age &gt; 60 years and t-MMSE 17 to 20</offsets></p><p><offsets xml_i="19329" xml_f="19370" txt_i="10288" txt_f="10329">2. Functionally independent (mRS 0 to 2).</offsets></p><p><offsets xml_i="19377" xml_f="19495" txt_i="10330" txt_f="10448">3. Ischemic stroke (IS, any Oxfordshire Community Stroke Project or Trial of Org10172 in Acute Stroke Treatment type [</offsets><xref ref-type="bibr" rid="B31"><offsets xml_i="19527" xml_f="19529" txt_i="10448" txt_f="10450">31</offsets></xref><offsets xml_i="19536" xml_f="19537" txt_i="10450" txt_f="10451">,</offsets><xref ref-type="bibr" rid="B32"><offsets xml_i="19569" xml_f="19571" txt_i="10451" txt_f="10453">32</offsets></xref><offsets xml_i="19578" xml_f="19622" txt_i="10453" txt_f="10497">]) or spontaneous intracerebral haemorrhage.</offsets></p><p><offsets xml_i="19629" xml_f="19728" txt_i="10498" txt_f="10597">4. Three to seven months post-event (to allow cognitive, neurological, BP and lipid stabilisation [</offsets><xref ref-type="bibr" rid="B33"><offsets xml_i="19760" xml_f="19762" txt_i="10597" txt_f="10599">33</offsets></xref><offsets xml_i="19769" xml_f="19793" txt_i="10599" txt_f="10623">], but avoid attrition).</offsets></p><p><offsets xml_i="19800" xml_f="19831" txt_i="10624" txt_f="10655">5. Systolic BP 125 to 170 mmHg.</offsets></p><p><offsets xml_i="19838" xml_f="19878" txt_i="10656" txt_f="10696">6. Total cholesterol (TC) 3 to 8 mmol/l.</offsets></p><p><offsets xml_i="19885" xml_f="20034" txt_i="10697" txt_f="10846">7. Presence of an informant (ideally two): partner, sibling, child, friend (for Informant Questionnaire on Cognitive Decline in the Elderly, IQCODE [</offsets><xref ref-type="bibr" rid="B34"><offsets xml_i="20066" xml_f="20068" txt_i="10846" txt_f="10848">34</offsets></xref><offsets xml_i="20075" xml_f="20078" txt_i="10848" txt_f="10851">]).</offsets></p><p><offsets xml_i="20085" xml_f="20129" txt_i="10852" txt_f="10896">8. Capacity and willingness to give consent.</offsets></p></sec><sec><title><offsets xml_i="20151" xml_f="20169" txt_i="10898" txt_f="10916">Exclusion criteria</offsets></title><p><offsets xml_i="20180" xml_f="20227" txt_i="10917" txt_f="10964">1. Participants not meeting inclusion criteria.</offsets></p><p><offsets xml_i="20234" xml_f="20262" txt_i="10965" txt_f="10993">2. Subarachnoid haemorrhage.</offsets></p><p><offsets xml_i="20269" xml_f="20356" txt_i="10994" txt_f="11081">3. Secondary intracranial haemorrhage (trauma, arterio-venous malformation, cavernoma).</offsets></p><p><offsets xml_i="20363" xml_f="20418" txt_i="11082" txt_f="11137">4. No CT/MR brain scan within ten days of index stroke.</offsets></p><p><offsets xml_i="20425" xml_f="20532" txt_i="11138" txt_f="11245">5. Inability to give consent or do study measures, for example, severe dysphasia, weakness of dominant arm.</offsets></p><p><offsets xml_i="20539" xml_f="20560" txt_i="11246" txt_f="11267">6. Profound deafness.</offsets></p><p><offsets xml_i="20567" xml_f="20618" txt_i="11268" txt_f="11316">7. Severe hypertension (systolic BP &gt; 170 mmHg).</offsets></p><p><offsets xml_i="20625" xml_f="20669" txt_i="11317" txt_f="11361">8. Definite need for ‘intensive’ BP control.</offsets></p><p><offsets xml_i="20676" xml_f="20726" txt_i="11362" txt_f="11409">9. Severe hypercholesterolemia (TC &gt; 8 mmol/l).</offsets></p><p><offsets xml_i="20733" xml_f="20812" txt_i="11410" txt_f="11489">10. Definite need for, or demonstrated intolerance of, ‘high intensity’ statin.</offsets></p><p><offsets xml_i="20819" xml_f="20881" txt_i="11490" txt_f="11552">11. Definite need for a cholinesterase inhibitor for dementia.</offsets></p><p><offsets xml_i="20888" xml_f="20955" txt_i="11553" txt_f="11620">12. Familial stroke associated with dementia, for example, CADASIL.</offsets></p><p><offsets xml_i="20962" xml_f="21063" txt_i="11621" txt_f="11716">13. Chronic renal failure: eGFR &lt; 45 (or eGFR &lt; 37 in people of African/Afro-Caribbean origin).</offsets></p><p><offsets xml_i="21070" xml_f="21165" txt_i="11717" txt_f="11809">14. Liver disease, ALT &gt; three times upper limit of normal, using local laboratories ranges.</offsets></p><p><offsets xml_i="21172" xml_f="21396" txt_i="11810" txt_f="12034">15. Ongoing participation in trials involving drug and/or devices. Participants already in another trial may be recruited to PODCAST, provided that participation in the other trial is complete prior to PODCAST randomisation.</offsets></p><p><offsets xml_i="21403" xml_f="21521" txt_i="12035" txt_f="12150">16. Any serious medical co-morbidity (for example, active malignancy) such that the life expectancy is &lt; 24 months.</offsets></p><p><offsets xml_i="21528" xml_f="21578" txt_i="12151" txt_f="12201">17. Clinically unstable at the time of enrollment.</offsets></p><p><offsets xml_i="21585" xml_f="21598" txt_i="12202" txt_f="12215">18. Dementia.</offsets></p></sec></sec><sec><title><offsets xml_i="21626" xml_f="21642" txt_i="12218" txt_f="12234">Informed consent</offsets></title><p><offsets xml_i="21653" xml_f="21926" txt_i="12235" txt_f="12508">All participants must have capacity, and be willing and able to provide written informed consent. Participants are screened for potential recruitment during their initial presentation to the hospital stroke services, and are given an information sheet explaining the study.</offsets></p><sec><title><offsets xml_i="21942" xml_f="21959" txt_i="12509" txt_f="12526">Screening consent</offsets></title><p><offsets xml_i="21970" xml_f="22104" txt_i="12527" txt_f="12661">Informed consent for formal screening is taken in hospital for conducting the following assessments, 8 to 26 weeks after their stroke:</offsets></p><p><offsets xml_i="22111" xml_f="22144" txt_i="12662" txt_f="12695">•Assessment of cognition - t-MMSE</offsets></p><p><offsets xml_i="22151" xml_f="22180" txt_i="12696" txt_f="12725">•Assessment of function - mRS</offsets></p><p><offsets xml_i="22187" xml_f="22254" txt_i="12726" txt_f="12793">•Blood test - fasting lipids, glucose, urea and electrolytes, HbA1c</offsets></p><p><offsets xml_i="22261" xml_f="22465" txt_i="12794" txt_f="12998">The availability of an informant (partner, sibling, child or friend), ideally with a backup, is key. Informants provide information on the participant’s prior cognitive state and decline (via the IQCODE).</offsets></p><p><offsets xml_i="22472" xml_f="22561" txt_i="12999" txt_f="13088">Both the patient and informant are then given information sheets to take away and review.</offsets></p></sec><sec><title><offsets xml_i="22583" xml_f="22595" txt_i="13090" txt_f="13102">Full consent</offsets></title><p><offsets xml_i="22606" xml_f="22884" txt_i="13103" txt_f="13381">Providing the patient fulfils the inclusion–exclusion criteria at the screening visit, full consent is taken at the baseline visit. This includes an assessment of capacity by telling the patient about the trial and then asking them to answer questions based on this information:</offsets></p><p><offsets xml_i="22891" xml_f="22914" txt_i="13382" txt_f="13405">•What condition? Stroke</offsets></p><p><offsets xml_i="22921" xml_f="22967" txt_i="13406" txt_f="13452">•What is the trial trying to prevent? Dementia</offsets></p><p><offsets xml_i="22974" xml_f="23037" txt_i="13453" txt_f="13516">•What are the interventions? Intensive BP and/or lipid lowering</offsets></p><p><offsets xml_i="23044" xml_f="23214" txt_i="13517" txt_f="13687">Following any questions about the trial, written informed consent of both the patient and informant is then performed. Patients may also give consent for two sub-studies:</offsets></p><p><offsets xml_i="23221" xml_f="23246" txt_i="13688" txt_f="13713">•Ambulatory BP monitoring</offsets></p><p><offsets xml_i="23253" xml_f="23274" txt_i="13714" txt_f="13735">•On-treatment CT scan</offsets></p><p><offsets xml_i="23281" xml_f="23455" txt_i="13736" txt_f="13910">Part of the consent process involves both the patient and informant agreeing to the latter assuming the right of proxy consent if the patient loses capacity during the trial.</offsets></p></sec></sec><sec><title><offsets xml_i="23483" xml_f="23496" txt_i="13913" txt_f="13926">Randomisation</offsets></title><p><offsets xml_i="23507" xml_f="23612" txt_i="13927" txt_f="14032">Eligible and consenting participants are randomised centrally using a secure internet site in real-time: </offsets><ext-link ext-link-type="uri" xlink:href="https://www.nottingham.ac.uk/~nszwww/podcast/podcasttrialdb/podcast_login.php"><offsets xml_i="23733" xml_f="23810" txt_i="14032" txt_f="14109">https://www.nottingham.ac.uk/~nszwww/podcast/podcasttrialdb/podcast_login.php</offsets></ext-link><offsets xml_i="23821" xml_f="23822" txt_i="14109" txt_f="14110">.</offsets></p><p><offsets xml_i="23829" xml_f="24199" txt_i="14111" txt_f="14481">The process of randomisation includes stratification, minimisation and simple randomisation, based on information gathered by the local recruiting investigators. Stratification and minimisation allow for improved matching at baseline: stratification allows variable categories to be treated as nested trials in their own right; minimisation increases statistical power [</offsets><xref ref-type="bibr" rid="B35"><offsets xml_i="24231" xml_f="24233" txt_i="14481" txt_f="14483">35</offsets></xref><offsets xml_i="24240" xml_f="24381" txt_i="14483" txt_f="14624">]. Simple randomisations reduce predictability. The minimisation variables will be used for adjustment of the primary and secondary analyses.</offsets></p><sec><title><offsets xml_i="24397" xml_f="24411" txt_i="14625" txt_f="14639">Stratification</offsets></title><p><offsets xml_i="24422" xml_f="24456" txt_i="14640" txt_f="14674">•Stroke type (IS, spontaneous ICH)</offsets></p><p><offsets xml_i="24463" xml_f="24603" txt_i="14675" txt_f="14815">Patients with IS are randomised to both BP lowering (intensive versus guideline) and lipid lowering (intensive versus guideline) strategies.</offsets></p><p><offsets xml_i="24610" xml_f="24701" txt_i="14816" txt_f="14907">Patients with ICH are randomised to BP lowering (intensive versus guideline) strategy only.</offsets></p></sec><sec><title><offsets xml_i="24723" xml_f="24776" txt_i="14909" txt_f="14962">Minimisation (on key prognostic/logistical variables)</offsets></title><p><offsets xml_i="24787" xml_f="24815" txt_i="14963" txt_f="14985">•Age (&lt; 70/&gt; 70 years)</offsets></p><p><offsets xml_i="24822" xml_f="24841" txt_i="14986" txt_f="15005">•Sex (female, male)</offsets></p><p><offsets xml_i="24848" xml_f="24868" txt_i="15006" txt_f="15026">•Dysphasia (no, yes)</offsets></p><p><offsets xml_i="24875" xml_f="24907" txt_i="15027" txt_f="15056">•Cognition, ACE-R (≥ 85/&lt; 85)</offsets></p><p><offsets xml_i="24914" xml_f="24953" txt_i="15057" txt_f="15090">•Systolic BP (&lt; 150 / &gt; 150 mmHg)</offsets></p><p><offsets xml_i="24960" xml_f="25002" txt_i="15091" txt_f="15130">•Total cholesterol (&lt; 4.0/≥ 4.0 mmol/L)</offsets></p><p><offsets xml_i="25009" xml_f="25042" txt_i="15131" txt_f="15164">•Function/dependency, mRS (0/≥ 1)</offsets></p><p><offsets xml_i="25049" xml_f="25081" txt_i="15165" txt_f="15197">•Brain region (subcortex/cortex)</offsets></p><p><offsets xml_i="25088" xml_f="25147" txt_i="15198" txt_f="15257">•Evidence of periventricular white matter lucency (no, yes)</offsets></p><p><offsets xml_i="25154" xml_f="25203" txt_i="15258" txt_f="15301">•Time since index stroke (&lt; 140/&gt; 140 days)</offsets></p><p><offsets xml_i="25210" xml_f="25256" txt_i="15302" txt_f="15345">•Number of antihypertensive drugs (&lt; 2/≥ 2)</offsets></p><p><offsets xml_i="25263" xml_f="25293" txt_i="15346" txt_f="15376">•Already on a statin (yes, no)</offsets></p></sec><sec><title><offsets xml_i="25315" xml_f="25335" txt_i="15378" txt_f="15398">Simple randomisation</offsets></title><p><offsets xml_i="25346" xml_f="25388" txt_i="15399" txt_f="15441">On 5% of patients at time of minimisation.</offsets></p></sec><sec><title><offsets xml_i="25410" xml_f="25430" txt_i="15443" txt_f="15463">Randomisation groups</offsets></title><p><offsets xml_i="25441" xml_f="25478" txt_i="15464" txt_f="15501">Study participants are randomized to:</offsets></p><p><offsets xml_i="25485" xml_f="25543" txt_i="15502" txt_f="15560">•Intensive versus guideline BP lowering - all participants</offsets></p><p><offsets xml_i="25550" xml_f="25616" txt_i="15561" txt_f="15627">•Intensive versus guideline lipid lowering - ischaemic stroke only</offsets></p><p><offsets xml_i="25623" xml_f="25684" txt_i="15628" txt_f="15689">As a result, patients can be randomised to one of six groups:</offsets></p><p><offsets xml_i="25691" xml_f="25768" txt_i="15690" txt_f="15767">1. Intensive BP lowering and intensive lipid lowering (ischaemic stroke only)</offsets></p><p><offsets xml_i="25775" xml_f="25852" txt_i="15768" txt_f="15845">2. Intensive BP lowering and guideline lipid lowering (ischaemic stroke only)</offsets></p><p><offsets xml_i="25859" xml_f="25899" txt_i="15846" txt_f="15886">3. Intensive BP lowering only (ICH only)</offsets></p><p><offsets xml_i="25906" xml_f="25983" txt_i="15887" txt_f="15964">4. Guideline BP lowering and intensive lipid lowering (ischaemic stroke only)</offsets></p><p><offsets xml_i="25990" xml_f="26067" txt_i="15965" txt_f="16042">5. Guideline BP lowering and guideline lipid lowering (ischaemic stroke only)</offsets></p><p><offsets xml_i="26074" xml_f="26114" txt_i="16043" txt_f="16083">6. Guideline BP lowering only (ICH only)</offsets></p><p><offsets xml_i="26121" xml_f="26501" txt_i="16084" txt_f="16464">Assuming that approximately 10% of patients will be enrolled with ICH, the distribution of patients between the six treatment groups will, for every 100 patients, approximate to 22.5% in each of the four groups of ischaemic stroke patients (intensive versus guideline BP; intensive versus guideline lipid) and 5% in each group of patients with ICH (intensive versus guideline BP).</offsets></p></sec></sec><sec><title><offsets xml_i="26529" xml_f="26542" txt_i="16467" txt_f="16480">Interventions</offsets></title><p><offsets xml_i="26553" xml_f="26756" txt_i="16481" txt_f="16684">The trial is assessing management strategies (‘intensive’ versus ‘guideline’) rather than particular drugs. All participants receive standard lifestyle advice and rehabilitation (as per NICECG 68, 2008 [</offsets><xref ref-type="bibr" rid="B36"><offsets xml_i="26788" xml_f="26790" txt_i="16684" txt_f="16686">36</offsets></xref><offsets xml_i="26797" xml_f="26963" txt_i="16686" txt_f="16852">]) including: diet, exercise, smoking advice, rehabilitation, psychological assessment and therapy, modification of all risk factors and other relevant interventions.</offsets></p><sec><title><offsets xml_i="26979" xml_f="26999" txt_i="16853" txt_f="16873">Guideline management</offsets></title><p><offsets xml_i="27010" xml_f="27170" txt_i="16874" txt_f="17034">Participants randomised to the guideline groups are managed by their general practitioner (GP) who follows national/international guidelines and local practice.</offsets></p></sec><sec><title><offsets xml_i="27192" xml_f="27213" txt_i="17036" txt_f="17057">Guideline BP lowering</offsets></title><p><offsets xml_i="27224" xml_f="27289" txt_i="17058" txt_f="17120">It is expected that GPs will aim for a systolic BP &lt; 140 mmHg.</offsets></p></sec><sec><title><offsets xml_i="27311" xml_f="27335" txt_i="17122" txt_f="17146">Guideline lipid lowering</offsets></title><p><offsets xml_i="27346" xml_f="27427" txt_i="17147" txt_f="17222">It is expected that GPs will aim for a LDL-c &lt; 3 mmol/l (or TC &lt; 5 mmol/l).</offsets></p></sec><sec><title><offsets xml_i="27449" xml_f="27469" txt_i="17224" txt_f="17244">Intensive management</offsets></title><p><offsets xml_i="27480" xml_f="28003" txt_i="17245" txt_f="17768">Participants in the intensive group are managed by the local hospital stroke research team and medications initiated by the local investigator and continued by the GP. The trial does not stipulate specific drugs but gives examples of drugs (and relevant doses) to use from the different drug classes. Guidance on which drugs to start and add, how to titrate, and how to manage participants with various contra-indications to medications, are included in algorithms; these are updated to include new information as relevant.</offsets></p><p><offsets xml_i="28010" xml_f="28356" txt_i="17769" txt_f="18115">Intensive BP and lipid management strategies may be attenuated or stopped if the patient or their informant withdraws consent, for safety, or if unacceptable adverse events develop. If the participant wishes to withdraw from treatment, they are requested to permit primary outcome data to be collected, ideally at the end of the follow-up period.</offsets></p></sec><sec><title><offsets xml_i="28378" xml_f="28399" txt_i="18117" txt_f="18138">Intensive BP lowering</offsets></title><p><offsets xml_i="28410" xml_f="28461" txt_i="18139" txt_f="18190">Two targets are required for intensive BP lowering:</offsets></p><p><offsets xml_i="28468" xml_f="28494" txt_i="18191" txt_f="18214">•Systolic BP &lt; 125 mmHg</offsets></p><p><offsets xml_i="28501" xml_f="28579" txt_i="18215" txt_f="18290">•Difference in systolic BP between intensive and guideline groups &gt; 10 mmHg</offsets></p><p><offsets xml_i="28586" xml_f="28766" txt_i="18291" txt_f="18471">Additional guidance on salt and alcohol restriction, and weight reduction is given. The intensive BP treatment algorithm is based on NICE guidelines relating to stroke (CG68 2008 [</offsets><xref ref-type="bibr" rid="B36"><offsets xml_i="28798" xml_f="28800" txt_i="18471" txt_f="18473">36</offsets></xref><offsets xml_i="28807" xml_f="28896" txt_i="18473" txt_f="18562">]), hypertension (CG127 2011) and type 2 diabetes (CG66 2006, partially updated by CG87 [</offsets><xref ref-type="bibr" rid="B37"><offsets xml_i="28928" xml_f="28930" txt_i="18562" txt_f="18564">37</offsets></xref><offsets xml_i="28937" xml_f="29157" txt_i="18564" txt_f="18784">]). The algorithm is only a guide and investigators may choose other medications depending on local policy and practice as long as they fit with the overall design of the trial, that is, to achieve intensive BP lowering.</offsets></p><p><offsets xml_i="29164" xml_f="29208" txt_i="18785" txt_f="18829">Suitable drug classes and example drugs are:</offsets></p><p><offsets xml_i="29215" xml_f="29463" txt_i="18830" txt_f="19078">•‘A’ = angiotensin converting enzyme inhibitor (ACE-I, for example, perindopril 2 to 8 mg daily (od), ramipril 1.25 to 5 mg twice daily (bd)) or angiotensin receptor antagonist (ARA, for example, losartan 25 to 100 mg od, candesartan 8 to 32 mg od)</offsets></p><p><offsets xml_i="29470" xml_f="29571" txt_i="19079" txt_f="19180">•‘B’ = beta (β)-receptor antagonist (for example, atenolol 25 to 100 mg od, bisoprolol 5 to 20 mg od)</offsets></p><p><offsets xml_i="29578" xml_f="29706" txt_i="19181" txt_f="19309">•‘C’ = calcium channel blocker (for example, amlodipine 5 to 10 mg od, nifedipine LA 30–60 mg od, verapamil SR 120 to 240 mg od)</offsets></p><p><offsets xml_i="29713" xml_f="29827" txt_i="19310" txt_f="19424">•‘D’ = diuretic (for example, bendroflumethiazide 2.5 mg od, hydrochlorothiazide 12.5 mg od, indapamide 2.5 mg od)</offsets></p><p><offsets xml_i="29834" xml_f="29941" txt_i="19425" txt_f="19532">•‘K’ = potassium-sparing diuretics (for example, spironolactone 12.5 to 100 mg od, amiloride 5 to 20 mg od)</offsets></p><p><offsets xml_i="29948" xml_f="30024" txt_i="19533" txt_f="19609">•‘Z’ = alpha (α)-receptor antagonists (for example, doxazosin 4 to 16 mg od)</offsets></p><p><offsets xml_i="30031" xml_f="30123" txt_i="19610" txt_f="19702">•‘M’ = centrally acting drugs (for example, moxonidine 200 to 600 μg daily in divided doses)</offsets></p><p><offsets xml_i="30130" xml_f="30208" txt_i="19703" txt_f="19781">In the absence of contraindications, participants should be started on either:</offsets></p><p><offsets xml_i="30215" xml_f="30290" txt_i="19782" txt_f="19857">•An ‘A’ drug, with subsequent addition of a ‘C’ then ‘D’ drug (as required)</offsets></p><p><offsets xml_i="30297" xml_f="30372" txt_i="19858" txt_f="19933">•A ‘C’ drug, with subsequent addition of an ‘A’ then ‘D’ drug (as required)</offsets></p><p><offsets xml_i="30379" xml_f="30473" txt_i="19934" txt_f="20028">If additional treatment is needed to reach target, fourth-line and additional options include:</offsets></p><p><offsets xml_i="30480" xml_f="30514" txt_i="20029" txt_f="20063">•Add a K or Z drug, then the other</offsets></p><p><offsets xml_i="30521" xml_f="30537" txt_i="20064" txt_f="20080">•Add an ‘M’ drug</offsets></p></sec><sec><title><offsets xml_i="30559" xml_f="30583" txt_i="20082" txt_f="20106">Intensive lipid lowering</offsets></title><p><offsets xml_i="30594" xml_f="30648" txt_i="20107" txt_f="20161">Two targets are required for intensive lipid lowering:</offsets></p><p><offsets xml_i="30655" xml_f="30688" txt_i="20162" txt_f="20192">•Calculated LDL-c &lt; 1.4 mmol/l</offsets></p><p><offsets xml_i="30695" xml_f="30770" txt_i="20193" txt_f="20265">•Difference in LDL-c between intensive and guideline groups &gt; 1.0 mmol/l</offsets></p><p><offsets xml_i="30777" xml_f="30893" txt_i="20266" txt_f="20382">If LDL-c cannot be calculated (for example, due to an elevated triglyceride level), targets for TC are used instead:</offsets></p><p><offsets xml_i="30900" xml_f="30919" txt_i="20383" txt_f="20399">•TC &lt; 3.1 mmol/l</offsets></p><p><offsets xml_i="30926" xml_f="30998" txt_i="20400" txt_f="20469">•Difference in TC between intensive and guideline groups &gt; 1.0 mmol/l</offsets></p><p><offsets xml_i="31005" xml_f="31070" txt_i="20470" txt_f="20535">Drug therapy for the intensive lipid arm will typically comprise:</offsets></p><p><offsets xml_i="31077" xml_f="31142" txt_i="20536" txt_f="20601">•A third-generation statin (for example, atorvastatin 80 mg od) [</offsets><xref ref-type="bibr" rid="B38"><offsets xml_i="31174" xml_f="31176" txt_i="20601" txt_f="20603">38</offsets></xref><offsets xml_i="31183" xml_f="31184" txt_i="20603" txt_f="20604">]</offsets></p><p><offsets xml_i="31191" xml_f="31221" txt_i="20605" txt_f="20635">•Then add ezetimibe (10 mg od)</offsets></p><p><offsets xml_i="31228" xml_f="31245" txt_i="20636" txt_f="20653">•Then add a resin</offsets></p><p><offsets xml_i="31252" xml_f="31440" txt_i="20654" txt_f="20842">Additional guidance on the use of plant stanols/sterols as part of meals, and weight reduction is given. The algorithm for intensive lipid reduction builds on NICE guidelines (CG67, 2008 [</offsets><xref ref-type="bibr" rid="B39"><offsets xml_i="31472" xml_f="31474" txt_i="20842" txt_f="20844">39</offsets></xref><offsets xml_i="31481" xml_f="31495" txt_i="20844" txt_f="20858">], ezetimibe [</offsets><xref ref-type="bibr" rid="B40"><offsets xml_i="31527" xml_f="31529" txt_i="20858" txt_f="20860">40</offsets></xref><offsets xml_i="31536" xml_f="31775" txt_i="20860" txt_f="21099">]). Again, the algorithm is only a guide and investigators may choose other treatment strategies depending on local policy and practice as long as they fit with the overall design of the trial, that is, to achieve intensive lipid lowering.</offsets></p></sec><sec><title><offsets xml_i="31797" xml_f="31810" txt_i="21101" txt_f="21114">Standard care</offsets></title><p><offsets xml_i="31821" xml_f="31927" txt_i="21115" txt_f="21221">Participants receive standard evidence-based care on top of the interventions, including (as appropriate):</offsets></p><p><offsets xml_i="31934" xml_f="32027" txt_i="21222" txt_f="21315">•IS: anticoagulation (cardioembolic stroke), antiplatelets (other IS), carotid endarterectomy</offsets></p></sec></sec><sec><title><offsets xml_i="32055" xml_f="32092" txt_i="21318" txt_f="21355">Blood pressure and lipid measurements</offsets></title><sec><title><offsets xml_i="32112" xml_f="32131" txt_i="21356" txt_f="21375">Blood pressure (BP)</offsets></title><p><offsets xml_i="32142" xml_f="32321" txt_i="21376" txt_f="21555">BP measurements are performed using a validated automated BP monitor, for example, Omron 705CP or 705CP II. These devices have been validated by the British Hypertension Society [</offsets><xref ref-type="bibr" rid="B41"><offsets xml_i="32353" xml_f="32355" txt_i="21555" txt_f="21557">41</offsets></xref><offsets xml_i="32362" xml_f="32452" txt_i="21557" txt_f="21647">], and were used in the positive ASCOT hypertension mega-trial involving 20,000 patients [</offsets><xref ref-type="bibr" rid="B42"><offsets xml_i="32484" xml_f="32486" txt_i="21647" txt_f="21649">42</offsets></xref><offsets xml_i="32493" xml_f="32702" txt_i="21649" txt_f="21858">]. Baseline and follow-up systolic and diastolic BP and heart rate (HR) readings are taken by trained staff in the non-paretic arm with the participant sitting (three readings) and then standing (one reading).</offsets></p></sec><sec><title><offsets xml_i="32724" xml_f="32755" txt_i="21860" txt_f="21891">Ambulatory BP monitoring (ABPM)</offsets></title><p><offsets xml_i="32766" xml_f="33091" txt_i="21892" txt_f="22217">In centers with ABPM equipment (for example, SpaceLabs 90207), participants have 24 hour ABPM performed at baseline and than on treatment every six months. Twenty-four hour, day-time (07.00 to 23.00 thrice hourly) and night-time (23.00 to 07.00 hourly) ABPM data are recorded. From these, a number of measures are calculated:</offsets></p><p><offsets xml_i="33098" xml_f="33142" txt_i="22218" txt_f="22262">•Mean SBP, DBP and HR for each time interval</offsets></p><p><offsets xml_i="33149" xml_f="33187" txt_i="22263" txt_f="22301">•Peak SBP and HR profile over 24 hours</offsets></p><p><offsets xml_i="33194" xml_f="33277" txt_i="22302" txt_f="22385">•BP and HR variation as standard deviation and coefficient of variation (= SD/Mean)</offsets></p></sec><sec><title><offsets xml_i="33299" xml_f="33316" txt_i="22387" txt_f="22404">Lipid measurement</offsets></title><p><offsets xml_i="33327" xml_f="33594" txt_i="22405" txt_f="22672">Fasting lipids are measured at an accredited clinical biochemistry laboratory. Fasting should be performed overnight and measurements made at least one month after the last change in lipid lowering therapy. Lipid measurements utilize standard techniques and comprise:</offsets></p><p><offsets xml_i="33601" xml_f="33604" txt_i="22673" txt_f="22676">•TC</offsets></p><p><offsets xml_i="33611" xml_f="33629" txt_i="22677" txt_f="22695">•Triglyceride (TG)</offsets></p><p><offsets xml_i="33636" xml_f="33660" txt_i="22696" txt_f="22720">•HDL cholesterol (HDL-c)</offsets></p><p><offsets xml_i="33667" xml_f="33686" txt_i="22721" txt_f="22740">•LDL-c (calculated)</offsets></p></sec></sec><sec><title><offsets xml_i="33714" xml_f="33729" txt_i="22743" txt_f="22758">Outcome measure</offsets></title><sec><title><offsets xml_i="33749" xml_f="33758" txt_i="22759" txt_f="22768">Screening</offsets></title><p><offsets xml_i="33769" xml_f="33871" txt_i="22769" txt_f="22871">An abbreviated form of the t-MMSE is used to screen patients so that those with dementia are excluded.</offsets></p></sec><sec><title><offsets xml_i="33893" xml_f="33908" txt_i="22873" txt_f="22888">Primary outcome</offsets></title><p><offsets xml_i="33919" xml_f="34102" txt_i="22889" txt_f="23072">The primary outcome is the Addenbrooke’s Cognitive Examination-Revised (ACE-R), which includes the MMSE. The ACE-R is measured at baseline and at each six-month research clinic visit.</offsets></p></sec><sec><title><offsets xml_i="34124" xml_f="34142" txt_i="23074" txt_f="23092">Secondary outcomes</offsets></title><p><offsets xml_i="34153" xml_f="34228" txt_i="23093" txt_f="23168">These are assessed at baseline and at each six-month research clinic visit.</offsets></p><p><offsets xml_i="34235" xml_f="34312" txt_i="23169" txt_f="23246">•Cognitive outcomes, participant: MoCA, TICS, Stroop and trail-making A and B</offsets></p><p><offsets xml_i="34319" xml_f="34359" txt_i="23247" txt_f="23287">•Cognitive assessment, informant: IQCODE</offsets></p><p><offsets xml_i="34366" xml_f="34403" txt_i="23288" txt_f="23322">•Cognitive impairment (ACE-R &lt; 89)</offsets></p><p><offsets xml_i="34410" xml_f="34475" txt_i="23323" txt_f="23385">•Cognitive decline (reduction in ACE-R by ≥ 10, or ACE-R &lt; 89)</offsets></p><p><offsets xml_i="34482" xml_f="34500" txt_i="23386" txt_f="23404">•Dementia (DSM IV)</offsets></p><p><offsets xml_i="34507" xml_f="34664" txt_i="23405" txt_f="23562">•Quality of life: Euro-Qol (EQ-5D and EQ-VAS). A health utility status will be calculated from the EQ-5D using the UK version of the time trade-off algorithm</offsets></p><p><offsets xml_i="34671" xml_f="34724" txt_i="23563" txt_f="23616">•Mood: Zung Depression rating Scale (ZDS, short form)</offsets></p><p><offsets xml_i="34731" xml_f="34789" txt_i="23617" txt_f="23675">•Function: modified Rankin Scale (mRS), Barthel Index (BI)</offsets></p><p><offsets xml_i="34796" xml_f="34872" txt_i="23676" txt_f="23752">•Health resource utilisation: face-to-face survey with participant and carer</offsets></p><p><offsets xml_i="34879" xml_f="34986" txt_i="23753" txt_f="23860">•Vascular event: stroke recurrence (by type), myocardial infarction (MI), peripheral arterial disease (PAD)</offsets></p><p><offsets xml_i="34993" xml_f="35022" txt_i="23861" txt_f="23890">•Serious adverse events (SAE)</offsets></p><p><offsets xml_i="35029" xml_f="35113" txt_i="23891" txt_f="23975">•Disposition: home, home with carer, residential home, nursing home, hospital, death</offsets></p><p><offsets xml_i="35120" xml_f="35162" txt_i="23976" txt_f="24018">•Haemodynamics: blood pressure, heart rate</offsets></p><p><offsets xml_i="35169" xml_f="35214" txt_i="24019" txt_f="24064">•Blood: fasting lipids (TC, TG, HDL-c, LDL-c)</offsets></p><p><offsets xml_i="35221" xml_f="35266" txt_i="24065" txt_f="24110">•Blood: Urea and electrolytes, glucose, HbA1c</offsets></p><p><offsets xml_i="35273" xml_f="35526" txt_i="24111" txt_f="24364">A head CT/MR scan is performed once participants have been in the trial at least twelve months (six months minimum). Comparison of this with the index stroke CT scan will allow changes to be identified: new stroke lesions, white matter disease, atrophy.</offsets></p><p><offsets xml_i="35533" xml_f="35747" txt_i="24365" txt_f="24579">Dementia, vascular events, and brains scans are adjudicated by experts blinded to treatment assignment. All patients are registered with the Office for National Statistics to identify death and its certified cause.</offsets></p></sec></sec><sec><title><offsets xml_i="35775" xml_f="35798" txt_i="24582" txt_f="24605">Sample size calculation</offsets></title><sec><title><offsets xml_i="35818" xml_f="35832" txt_i="24606" txt_f="24620">Start-up phase</offsets></title><p><offsets xml_i="35843" xml_f="36235" txt_i="24621" txt_f="25013">Recruitment of 600 participants (300 per BP group, approximately, 270 per statin group) will be sufficient to demonstrate adequacy in recruitment of sites and participants, whether sufficient on-treatment differences in BP and lipids can be obtained and maintained, and whether cognition can be assessed satisfactorily. No formal sample size calculation is relevant to this part of the trial.</offsets></p></sec><sec><title><offsets xml_i="36257" xml_f="36267" txt_i="25015" txt_f="25025">Main phase</offsets></title><p><offsets xml_i="36278" xml_f="36479" txt_i="25026" txt_f="25227">Using the ACE-R, expanded to include death, as the primary outcome, the whole trial (start-up plus main phases) will need a sample size of 3,400 (1,700 per BP group) post-stroke participants, assuming:</offsets></p><p><offsets xml_i="36486" xml_f="36507" txt_i="25228" txt_f="25249">•Significance, α = 5%</offsets></p><p><offsets xml_i="36514" xml_f="36532" txt_i="25250" txt_f="25268">•Power (1-β) = 90%</offsets></p><p><offsets xml_i="36539" xml_f="36674" txt_i="25269" txt_f="25404">•Rate of cognitive impairment or death in guideline BP group = 25% at five years (main trial, average length of follow-up four years) [</offsets><xref ref-type="bibr" rid="B34"><offsets xml_i="36706" xml_f="36708" txt_i="25404" txt_f="25406">34</offsets></xref><offsets xml_i="36715" xml_f="36716" txt_i="25406" txt_f="25407">]</offsets></p><p><offsets xml_i="36723" xml_f="36903" txt_i="25408" txt_f="25588">•Rate of cognitive impairment or death in ‘intensive’ BP group = 20%, that is, absolute risk reduction (ARR) = 5% (number-needed-to-treat = 20), relative risk reduction (RRR) = 20%</offsets></p><p><offsets xml_i="36910" xml_f="36935" txt_i="25589" txt_f="25614">•Losses to follow-up = 3%</offsets></p><p><offsets xml_i="36942" xml_f="37449" txt_i="25615" txt_f="26122">Hence, 765 participants (0.225 × 3,400) are anticipated to develop cognitive impairment or die. The sample size allows a smaller but clinically worthwhile decline in cognitive decline to be identified with 80% power, that is, ARR = 4.5% (RRR 18%). Since there are less existing data on the effect of cholesterol lowering on cognition, the statin factor will assume the same RRR (20%) but have less power (approximately 86%) since it will only involve participants with ischemic stroke (approximately 3,060).</offsets></p><p><offsets xml_i="37456" xml_f="37688" txt_i="26123" txt_f="26355">Changing from a binary to ordinal analysis of cognitive outcomes may allow for a reduction in sample size of up to 30%, as seen in the ‘Optimizing Analysis of Stroke Trials’ (OAST) collaboration for functional outcome after stroke [</offsets><xref ref-type="bibr" rid="B43"><offsets xml_i="37720" xml_f="37722" txt_i="26355" txt_f="26357">43</offsets></xref><offsets xml_i="37729" xml_f="37894" txt_i="26357" txt_f="26522">]. Providing ordinal analysis appears to be more efficient than binary analysis for cognition data, the trial will be re-sized according to the method of Whitehead [</offsets><xref ref-type="bibr" rid="B44"><offsets xml_i="37926" xml_f="37928" txt_i="26522" txt_f="26524">44</offsets></xref><offsets xml_i="37935" xml_f="38032" txt_i="26524" txt_f="26621">]. Analyses will be adjusted for the covariates since this approach increases statistical power [</offsets><xref ref-type="bibr" rid="B45"><offsets xml_i="38064" xml_f="38066" txt_i="26621" txt_f="26623">45</offsets></xref><offsets xml_i="38073" xml_f="38335" txt_i="26623" txt_f="26885">] and is recommended by the European Agency for the Evaluation of Medicinal Products (EMEA) Ref CPMP/EWP/560/98). Any such decision to change will be performed prior to database lock, blinded to treatment, and defined explicitly in the Statistical Analysis Plan.</offsets></p></sec></sec><sec><title><offsets xml_i="38363" xml_f="38383" txt_i="26888" txt_f="26908">Statistical analysis</offsets></title><sec><title><offsets xml_i="38403" xml_f="38432" txt_i="26909" txt_f="26938">Feasibility of start-up phase</offsets></title><p><offsets xml_i="38443" xml_f="38709" txt_i="26939" txt_f="27205">The feasibility criteria listed in section 2.4.1 are reviewed during the trial. A review at 24 months found that there was no chance of recruiting 600 patients during the internal pilot and that, therefore, the planned main phase should be cancelled (see section 4).</offsets></p></sec><sec><title><offsets xml_i="38731" xml_f="38767" txt_i="27207" txt_f="27243">Comparisons between treatment groups</offsets></title><p><offsets xml_i="38778" xml_f="38861" txt_i="27244" txt_f="27327">Outcomes will be compared between the treatment groups by intention-to-treat (ITT):</offsets></p><p><offsets xml_i="38868" xml_f="38907" txt_i="27328" txt_f="27367">•Intensive versus guideline BP lowering</offsets></p><p><offsets xml_i="38914" xml_f="38956" txt_i="27368" txt_f="27410">•Intensive versus guideline lipid lowering</offsets></p><p><offsets xml_i="38963" xml_f="39380" txt_i="27411" txt_f="27828">Analyses will be adjusted for baseline values and stroke type, age, sex, SBP, TC, and time from stroke to randomization. Continuous covariates (age, SBP, TC, time) will be used with their raw data, that is, not dichotomized. (The full set of stratification and minimization variables listed in section Randomisation will not be used for adjustment because of the limited anticipated sample size of approximately 100).</offsets></p></sec><sec><title><offsets xml_i="39402" xml_f="39425" txt_i="27830" txt_f="27853">Missing data, and death</offsets></title><p><offsets xml_i="39436" xml_f="39941" txt_i="27854" txt_f="28359">Missing data will not be imputed. Participants who die will be assigned discrete values for outcome measures with a value worse than any living value (as is standard for mRS, BI). This avoids giving death the same value as the worst possible outcome when alive (best to worst) or, worse, excluding patients who die (since many dementia trials have been confounded by losses to death). Hence, patients who die will be included in all analyses. The EQ-5D Health Utility State (HUS) gives death a score of 0.</offsets></p><p><offsets xml_i="39948" xml_f="40026" txt_i="28360" txt_f="28438">•Addenbrooke’s Cognitive Examination-Revised (ACE-R), 100 to 0 with death = −1</offsets></p><p><offsets xml_i="40033" xml_f="40095" txt_i="28439" txt_f="28501">•Mini-Mental State Examination (MMSE), 30 to 0 with death = −1</offsets></p><p><offsets xml_i="40102" xml_f="40177" txt_i="28502" txt_f="28577">•Telephone-Mini Mental Status Examination (t-MMSE), 18 to 0 with death = −1</offsets></p><p><offsets xml_i="40184" xml_f="40257" txt_i="28578" txt_f="28651">•Telephone Interview for Cognitive Status (TICS), 37 to 0 with death = −1</offsets></p><p><offsets xml_i="40264" xml_f="40307" txt_i="28652" txt_f="28695">•Stroop (accuracy), 24 to 0 with death = −1</offsets></p><p><offsets xml_i="40314" xml_f="40340" txt_i="28696" txt_f="28722">•Trail-making (accuracy) [</offsets><xref ref-type="bibr" rid="B46"><offsets xml_i="40372" xml_f="40374" txt_i="28722" txt_f="28724">46</offsets></xref><offsets xml_i="40381" xml_f="40407" txt_i="28724" txt_f="28750">], 25 to 0 with death = −1</offsets></p><p><offsets xml_i="40414" xml_f="40465" txt_i="28751" txt_f="28802">•Modified Rankin Scale (mRS), 0 to 5 with death = 6</offsets></p><p><offsets xml_i="40472" xml_f="40517" txt_i="28803" txt_f="28848">•Barthel Index (BI), 100 to 0 with death = −5</offsets></p><p><offsets xml_i="40524" xml_f="40593" txt_i="28849" txt_f="28918">•EuroQol EQ-5D Health Utility State (HUS), 1 to −0.594 with death = 0</offsets></p><p><offsets xml_i="40600" xml_f="40664" txt_i="28919" txt_f="28983">•EuroQol Visual Analog Scale (EQ-VAS), 100 to 0 with death = −1.</offsets></p><p><offsets xml_i="40671" xml_f="40729" txt_i="28984" txt_f="29042">•Zung Depression Scale (ZDS), 25 to 100 with death = 102.5</offsets></p><p><offsets xml_i="40736" xml_f="40792" txt_i="29043" txt_f="29099">•Verbal fluency (animal naming), x to 0, with death = −1</offsets></p></sec><sec><title><offsets xml_i="40814" xml_f="40829" txt_i="29101" txt_f="29116">Primary outcome</offsets></title><p><offsets xml_i="40840" xml_f="41083" txt_i="29117" txt_f="29360">Comparison of ACE-R (extended to include death - section Missing data, and death) between ‘intensive’ and ‘guideline’ BP/lipid lowering groups using multiple linear regression and with adjustment (section Comparisons between treatment groups).</offsets></p></sec><sec><title><offsets xml_i="41105" xml_f="41123" txt_i="29362" txt_f="29380">Secondary analyses</offsets></title><p><offsets xml_i="41134" xml_f="41475" txt_i="29381" txt_f="29722">Dichotomous, ordered categorical, continuous and time to event data will be analysed using binary logistic regression (BLR), ordinal logistic regression (OLR), multiple linear regression (MLR) or Cox regression (CR) respectively, and with adjustment (section Comparisons between treatment groups). 95% confidence intervals will be given and </offsets><italic><offsets xml_i="41483" xml_f="41484" txt_i="29722" txt_f="29723">P</offsets></italic><offsets xml_i="41493" xml_f="41549" txt_i="29723" txt_f="29776"> &lt; 0.05 will be considered statistically significant.</offsets></p><p><offsets xml_i="41556" xml_f="41758" txt_i="29777" txt_f="29979">The proportion of participants with cognitive impairment or who have died, and cognitive decline or died, will be compared between the treatment groups, as done previously for MMSE (a subset of ACE-R) [</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="41790" xml_f="41792" txt_i="29979" txt_f="29981">15</offsets></xref><offsets xml_i="41799" xml_f="41800" txt_i="29981" txt_f="29982">,</offsets><xref ref-type="bibr" rid="B28"><offsets xml_i="41832" xml_f="41834" txt_i="29982" txt_f="29984">28</offsets></xref><offsets xml_i="41841" xml_f="41956" txt_i="29984" txt_f="30099">]. Nevertheless, where possible, continuous or ordinal outcomes will be used in preference to dichotomous outcomes.</offsets></p></sec></sec><sec><title><offsets xml_i="41984" xml_f="42006" txt_i="30102" txt_f="30124">Governance and funding</offsets></title><sec><title><offsets xml_i="42026" xml_f="42056" txt_i="30125" txt_f="30155">Trial Steering Committee (TSC)</offsets></title><p><offsets xml_i="42067" xml_f="42232" txt_i="30156" txt_f="30321">The TSC provides leadership for the trial and determines and monitors the overall strategy. It meets annually, and has teleconference or Email discussions as needed.</offsets></p></sec><sec><title><offsets xml_i="42254" xml_f="42285" txt_i="30323" txt_f="30354">Data Monitoring Committee (DMC)</offsets></title><p><offsets xml_i="42296" xml_f="42489" txt_i="30355" txt_f="30548">The DMC reviews unblinded data annually in respect of safety and efficacy, and considers the study in the context of other trials of dementia prevention post-stroke. It meets at least annually.</offsets></p></sec><sec><title><offsets xml_i="42511" xml_f="42543" txt_i="30550" txt_f="30582">Trial Management Committee (TMC)</offsets></title><p><offsets xml_i="42554" xml_f="42791" txt_i="30583" txt_f="30820">The Trial Management Committee (TMC) runs the trial, with meetings every three weeks. It is unblinded to BP and lipid levels, and communicates with the Trial Steering Committee (TSC) and investigators as to whether targets are being met.</offsets></p></sec><sec><title><offsets xml_i="42813" xml_f="42836" txt_i="30822" txt_f="30845">Adjudication committees</offsets></title><p><offsets xml_i="42847" xml_f="42909" txt_i="30846" txt_f="30908">All adjudication is performed blinded to treatment assignment:</offsets></p><p><offsets xml_i="42916" xml_f="43019" txt_i="30909" txt_f="31012">•Dementia is adjudicated by a group of three individuals (AB, CB, GF); each adjudicator sees each event</offsets></p><p><offsets xml_i="43026" xml_f="43137" txt_i="31013" txt_f="31124">•Vascular events are adjudicated by a group of three individuals (PP, AM, RH); each adjudicator sees each event</offsets></p><p><offsets xml_i="43144" xml_f="43219" txt_i="31125" txt_f="31200">•Serious adverse events are adjudicated by one of two adjudicators (NS, TE)</offsets></p></sec><sec><title><offsets xml_i="43241" xml_f="43248" txt_i="31202" txt_f="31209">Sponsor</offsets></title><p><offsets xml_i="43259" xml_f="43311" txt_i="31210" txt_f="31262">The University of Nottingham is the trial’s sponsor.</offsets></p></sec><sec><title><offsets xml_i="43333" xml_f="43340" txt_i="31264" txt_f="31271">Funding</offsets></title><p><offsets xml_i="43351" xml_f="43467" txt_i="31272" txt_f="31388">The start-up phase of PODCAST is funded jointly and equally by the UK Alzheimer’s Society and UK Stroke Association.</offsets></p></sec></sec></sec><sec><title><offsets xml_i="43501" xml_f="43513" txt_i="31392" txt_f="31404">Trial Status</offsets></title><p><offsets xml_i="43524" xml_f="43720" txt_i="31405" txt_f="31601">A lower than planned recruitment of sites and patients has meant that the aspiration to recruit 600 patients over two years has not been realized. A number of reasons explain the poor recruitment:</offsets></p><p><offsets xml_i="43727" xml_f="44321" txt_i="31602" txt_f="32196">•Research governance issues. The trial requires both acute hospital trusts (who identify patients, manage intensive BP and/or lipid lowering, and perform clinic follow-ups) and general practices, through Primary Care Trusts (PCTs, who manage guideline BP and/or lipid management), to sign-up. In general, each acute trust is associated with between one and three PCTs so that approval for each recruiting site requires between two and four agreements and contracts. It has proved difficult to coordinate the agreement to deliver the study in a locality between these acute and community trusts.</offsets></p><p><offsets xml_i="44328" xml_f="44524" txt_i="32197" txt_f="32393">•NHS Excess Treatment Costs. PCTs were often unwilling to approve payment of treatment costs, often citing the cost of atorvastatin (which is now generic but was not so at the start of the trial).</offsets></p><p><offsets xml_i="44531" xml_f="44758" txt_i="32394" txt_f="32621">•Long-term follow-up. Once a cohort of patients is recruited, each patient needs follow-up (which typically last two and a half hours) every six months, thereby placing a considerable work load on research staff at acute sites.</offsets></p><p><offsets xml_i="44765" xml_f="44823" txt_i="32622" txt_f="32680">•Changes to the original protocol are summarised in Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="44855" xml_f="44856" txt_i="32680" txt_f="32681">1</offsets></xref></p><table-wrap position="float" id="T1"><label><offsets xml_i="44911" xml_f="44918" txt_i="32682" txt_f="32689">Table 1</offsets></label><caption><p><offsets xml_i="44938" xml_f="44993" txt_i="32689" txt_f="32744">Protocol amendments and other changes to trial practice</offsets></p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="left"></col><col align="left"></col><col align="left"></col></colgroup><thead valign="top"><tr><th align="left"><bold><offsets xml_i="45219" xml_f="45228" txt_i="32745" txt_f="32754">Criterion</offsets></bold></th><th align="left"><bold><offsets xml_i="45263" xml_f="45280" txt_i="32754" txt_f="32771">Previous versions</offsets></bold></th><th align="left"><bold><offsets xml_i="45315" xml_f="45337" txt_i="32771" txt_f="32793">Current version/status</offsets></bold></th><th align="left"><bold><offsets xml_i="45372" xml_f="45378" txt_i="32793" txt_f="32799">Reason</offsets></bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom"><bold><offsets xml_i="45466" xml_f="45482" txt_i="32799" txt_f="32815">Protocol changes</offsets></bold><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="45536" xml_f="45537" txt_i="32816" txt_f="32817"> </offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="45584" xml_f="45585" txt_i="32818" txt_f="32819"> </offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="45632" xml_f="45633" txt_i="32820" txt_f="32821"> </offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="45689" xml_f="45724" txt_i="32822" txt_f="32857">Posterior circulation stroke (POCS)</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="45771" xml_f="45779" txt_i="32858" txt_f="32866">Excluded</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="45826" xml_f="45834" txt_i="32867" txt_f="32875">Included</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="45881" xml_f="45973" txt_i="32876" txt_f="32968">To expand the inclusion criteria; posterior circulation stroke can lead to cognitive decline</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="46029" xml_f="46053" txt_i="32969" txt_f="32993">Exclusion of NYHA 3 or 4</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="46100" xml_f="46119" txt_i="32994" txt_f="33013">Exclusion criterion</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="46166" xml_f="46173" txt_i="33014" txt_f="33021">Removed</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="46220" xml_f="46240" txt_i="33022" txt_f="33042">To simplify protocol</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="46296" xml_f="46308" txt_i="33043" txt_f="33055">LDL-c target</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="46355" xml_f="46370" txt_i="33056" txt_f="33068">&lt; 2.0 mmol/l</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="46417" xml_f="46432" txt_i="33069" txt_f="33081">&lt; 1.4 mmol/l</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="46479" xml_f="46531" txt_i="33082" txt_f="33131">Half of patients already at LDL-c &lt; 2 at baseline</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="46587" xml_f="46604" txt_i="33132" txt_f="33149">Total cholesterol</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="46651" xml_f="46664" txt_i="33150" txt_f="33160">&lt; 4.0 mmol</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="46711" xml_f="46726" txt_i="33161" txt_f="33173">&lt; 3.1 mmol/l</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="46773" xml_f="46778" txt_i="33174" txt_f="33179">Ditto</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="46834" xml_f="46852" txt_i="33180" txt_f="33198">Glucose monitoring</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="46899" xml_f="46900" txt_i="33199" txt_f="33200"> </offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="46947" xml_f="46961" txt_i="33201" txt_f="33215">Glucose, HbA1C</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="47008" xml_f="47071" txt_i="33216" txt_f="33279">Some BP and lipid drugs may reduce, or cause, diabetes mellitus</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="47127" xml_f="47142" txt_i="33280" txt_f="33295">Quality of life</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="47189" xml_f="47195" txt_i="33296" txt_f="33302">DEMQOL</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="47242" xml_f="47249" txt_i="33303" txt_f="33310">Removed</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="47296" xml_f="47316" txt_i="33311" txt_f="33331">To simplify protocol</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="47372" xml_f="47381" txt_i="33332" txt_f="33341">Screening</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="47428" xml_f="47445" txt_i="33342" txt_f="33359">As telephone call</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="47492" xml_f="47516" txt_i="33360" txt_f="33384">As research clinic visit</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="47563" xml_f="47607" txt_i="33385" txt_f="33429">To reduce recruitment of ineligible patients</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="47663" xml_f="47699" txt_i="33430" txt_f="33466">Time from screening to randomisation</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="47746" xml_f="47753" txt_i="33467" txt_f="33474">2 weeks</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="47800" xml_f="47806" txt_i="33475" txt_f="33481">1 week</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="47853" xml_f="47878" txt_i="33482" txt_f="33507">To accelerate recruitment</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="47934" xml_f="47957" txt_i="33508" txt_f="33531">Guideline statin dosage</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="48004" xml_f="48059" txt_i="33532" txt_f="33587">Simvastatin 40 mg, pravastatin 40 mg, fluvastatin 40 mg</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="48106" xml_f="48179" txt_i="33588" txt_f="33661">Simvastatin 10 to 40 mg, pravastatin 10 to 40 mg, fluvastatin 10 to 80 mg</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="48226" xml_f="48286" txt_i="33662" txt_f="33722">To reflect NICE guidelines on lipid management (CG 67, 2008)</offsets><hr></hr></td></tr><tr><td rowspan="3" align="left" valign="bottom"><offsets xml_i="48354" xml_f="48375" txt_i="33723" txt_f="33744">Statin classification</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="48422" xml_f="48439" txt_i="33745" txt_f="33762">Guideline statin:</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="48486" xml_f="48503" txt_i="33763" txt_f="33780">Guideline statin:</offsets><hr></hr></td><td rowspan="3" align="left" valign="bottom"><offsets xml_i="48562" xml_f="48625" txt_i="33781" txt_f="33844">To clarify intensive versus guideline lipid lowering management</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="48681" xml_f="48768" txt_i="33845" txt_f="33929">simvastatin &lt; 40 mg, pravastatin any dose, fluvastatin any dose, atorvastatin 10 mg.</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="48815" xml_f="48901" txt_i="33930" txt_f="34016">simvastatin ≤ 40 mg, pravastatin any dose, fluvastatin any dose, atorvastatin ≤ 20 mg.</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="48957" xml_f="48995" txt_i="34017" txt_f="34055">Intensive statin: atorvastatin ≤ 40 mg</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="49042" xml_f="49106" txt_i="34056" txt_f="34117">Intensive statin: atorvastatin &gt; 20 mg, rosuvastatin any dose</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="49162" xml_f="49204" txt_i="34118" txt_f="34160">Trial duration and participant involvement</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="49251" xml_f="49258" txt_i="34161" txt_f="34168">8 years</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="49305" xml_f="49312" txt_i="34169" txt_f="34176">4 years</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="49359" xml_f="49419" txt_i="34177" txt_f="34237">To shorten trial since the main phase is no longer justified</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="49475" xml_f="49518" txt_i="34238" txt_f="34281">BP and lipid management in follow-up visits</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="49565" xml_f="49566" txt_i="34282" txt_f="34283"> </offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="49613" xml_f="49710" txt_i="34284" txt_f="34381">‘Floating’ visit at any time outside the planned visits at 3, 6, 12, 18, 24, 30, 36 and 42 months</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="49757" xml_f="49814" txt_i="34382" txt_f="34439">To allow enhanced escalation of treatment, as appropriate</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="49870" xml_f="49913" txt_i="34440" txt_f="34483">Baseline and follow-up BP and HR monitoring</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="49960" xml_f="49998" txt_i="34484" txt_f="34522">Three measurements in rapid succession</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="50045" xml_f="50105" txt_i="34523" txt_f="34583">Four measurements in rapid succession including one standing</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="50152" xml_f="50182" txt_i="34584" txt_f="34614">To detect postural hypotension</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="50238" xml_f="50265" txt_i="34615" txt_f="34642">Neuroimaging sub-study scan</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="50312" xml_f="50313" txt_i="34643" txt_f="34644"> </offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="50360" xml_f="50437" txt_i="34645" txt_f="34722">CT scan on treatment (plus collection of any clinical scans during treatment)</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="50484" xml_f="50544" txt_i="34723" txt_f="34783">To detect potential affects on atrophy, white matter changes</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="50600" xml_f="50616" txt_i="34784" txt_f="34800">Follow-up visits</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="50663" xml_f="50732" txt_i="34801" txt_f="34870">Seen in clinic once a year with interval blinded telephone follow-up.</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="50779" xml_f="50813" txt_i="34871" txt_f="34905">Seen in clinic once every 6 months</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="50860" xml_f="50937" txt_i="34906" txt_f="34983">To assess latest BP and/or lipid levels and escalate treatment as appropriate</offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="50993" xml_f="51006" txt_i="34984" txt_f="34997">Other changes</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="51053" xml_f="51054" txt_i="34998" txt_f="34999"> </offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="51101" xml_f="51102" txt_i="35000" txt_f="35001"> </offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="51149" xml_f="51150" txt_i="35002" txt_f="35003"> </offsets><hr></hr></td></tr><tr><td align="left" valign="bottom"><offsets xml_i="51206" xml_f="51228" txt_i="35004" txt_f="35026">Minimisation variables</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="51275" xml_f="51348" txt_i="35027" txt_f="35100">As in section Minimisation (on key prognostic/logistical variables) above</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="51395" xml_f="51418" txt_i="35101" txt_f="35124">Age, systolic BP, LDL-c</offsets><hr></hr></td><td align="left" valign="bottom"><offsets xml_i="51465" xml_f="51523" txt_i="35125" txt_f="35183">Small trial size precluded numerous minimisation variables</offsets><hr></hr></td></tr><tr><td align="left"><offsets xml_i="51563" xml_f="51578" txt_i="35184" txt_f="35199">Email reminders</offsets></td><td align="left"><offsets xml_i="51600" xml_f="51601" txt_i="35200" txt_f="35201"> </offsets></td><td align="left"><offsets xml_i="51623" xml_f="51653" txt_i="35202" txt_f="35232">Twice yearly to investigators.</offsets></td><td align="left"><offsets xml_i="51675" xml_f="51787" txt_i="35233" txt_f="35345">To highlight the need to achieve targets in BP and lipid lowering in patients randomised to intensive management</offsets></td></tr></tbody></table></table-wrap></sec><sec><title><offsets xml_i="51844" xml_f="51857" txt_i="35347" txt_f="35360">Abbreviations</offsets></title><p><offsets xml_i="51868" xml_f="53503" txt_i="35361" txt_f="36996">PODCAST: Prevention of Decline in Cognition after Stroke Trial; TICS: Telephone Interview for Cognitive Status; MOCA: Montreal Cognitive Assessment; ACE-R: Addenbrooke’s Cognitive Examintaion-revised; MMSE: Mini-Mental State Examination; od: once daily; bd: Twice daily; PCT: Primary Care Trust; IQCODE: Informant Questionnaire on Cognitive Decline in the Elderly; DSM IV: Diagnostic and Statistical Manual of Mental Disorders edition IV; BP: Blood pressure; SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure; ABPM: Ambulatory Blood Pressure Monitoring; HR: Heart rate; MI: Myocardial infarction; PAD: Peripheral arterial disease; eGFR: estimated Glomerular Filtration Rate; ALT: ALanine Transaminase; IS: Ischaemic stroke; ICH: Intracerebral haemorrhage; SAE: Serious adverse events; GP: General practitioner; WMH: White matter hyperintensities; POCS: Posterior Circulation Stroke; ARR: Absolute risk reduction; NNT: Number-needed-to-treat; RRR: Relative risk reduction; ITT: Intention-to-treat; CT: Computed Tomography; MR: Magnetic Resonance imaging; TC: Total cholesterol; TG: Triglycerides; HDL-c: High Density Lipoprotein cholesterol; LDL-c: Low Density Lipoprotein cholesterol; OAST: Optimizing Analysis of Stroke Trials’; EMEA: European Agency for the Evaluation of Medicinal Products; BLR: Binary logistic regression; OLR: Ordinal logistic regression; MLR: Multiple linear regression; CR: Cox regression; mRS: Modified Rankin Scale; BI: Barthel Index; HUS: EuroQol EQ-5D Health Utility State; ZDS: Zung Depression Scale; TMC: Trial Management Committee; TSC: Trial Steering Committee; DMC: Data Monitoring Committee.</offsets></p></sec><sec><title><offsets xml_i="53525" xml_f="53544" txt_i="36998" txt_f="37017">Competing interests</offsets></title><p><offsets xml_i="53555" xml_f="53613" txt_i="37018" txt_f="37076">The authors declare that they have no competing interests.</offsets></p></sec><sec><title><offsets xml_i="53635" xml_f="53657" txt_i="37078" txt_f="37100">Authors’ contributions</offsets></title><p><offsets xml_i="53668" xml_f="53940" txt_i="37101" txt_f="37373">DJB and PB drafted the manuscript and updated the current literature for the background section. Statistical advice was provided by SP. CB, PB, AB, GF, JM, PP, SP, JR, RS and JW designed the study and wrote the protocol. All authors read and improved the final manuscript.</offsets></p></sec></body><back><sec><title>Acknowledgements</title><sec><title>Trial steering committee</title><p>Independent experts: John O'Brien (TSC Chair, Cambridge), Stephen Ball (Cardiology, Leeds).</p><p>Grant holders: Philip Bath (Stroke, Chief Investigator - lipid lowering arm, Nottingham), Gary Ford (Stroke, Chief Investigator - BP lowering arm, Newcastle), Clive Ballard (Psychiatry, London), Alistair Burns (Psychiatry, Manchester), Jonathan Mant (Public Health, Cambridge), Peter Passmore (Geriatrics, Belfast), John Reckless (Lipids, Bath), Rob Stewart (Psychiatry, London), Joanna Wardlaw (Neuroradiology, Edinburgh), Nikola Sprigg (Stroke, Nottingham).</p><p>Patient and Carer representatives: Dave Hanbury, John Murray, Andrew Pepper</p><p>Funders' representative: Susanne Sorensen/James Pickett (Alzheimer’s Society), Peter Coleman (The Stroke Association).</p><p>Sponsor representative: Angela Shone (University of Nottingham).</p></sec><sec><title>Data monitoring committee</title><p>John Geddes (Chair, Oxford), Jan Staessen (Hypertension, Leuven), Chris Weir (Statistics, Edinburgh), Lydia Fox (non-voting, statistics, Nottingham).</p></sec><sec><title>Cognition/dementia adjudicators</title><p>Alistair Burns (Chair, Psychiatry, Manchester), Clive Ballard (Psychiatry, London), Gary Ford (Stroke, Newcastle).</p></sec><sec><title>Vascular events adjudicators</title><p>Peter Passmore (Chair, Geriatrics, Belfast), Amit Mistri (Stroke, Leicester), Rob Henderson (Cardiology, Nottingham).</p></sec><sec><title>Serious adverse event adjudicator</title><p>Nikola Sprigg (Stroke, Nottingham), Tim England (Stroke, Derby/Nottingham).</p></sec><sec><title>Neuroimaging</title><p>Joanna Wardlaw (Chair, Neuroradiology, Edinburgh), Dan Blackburn (Neurology, Sheffield).</p></sec><sec><title>Health economics</title><p>Paul McCrone, Martin Knapp (London).</p></sec><sec><title>Statisticians</title><p>Stuart Pocock (Consultant, London), Lydia Fox (Analyst, Nottingham).</p></sec><sec><title>Programming/database management</title><p>Lee Haywood, Liz Walker, Richard Dooley (Nottingham).</p></sec><sec><title>Sponsor</title><p>University of Nottingham.</p></sec><sec><title>Participating sites (who have given research ethics approval)</title><p>Aberdeen Royal Infirmary (NHS Grampian).</p><p>Aintree Hospitals NHS Foundation Trust.</p><p>Birmingham Heartlands &amp; Solihull Hospitals NHS Trust.</p><p>Bradford Teaching Hospitals NHS Foundation Trust.</p><p>Chesterfield Royal Hospital NHS Foundation Trust.</p><p>Derby Hospitals NHS Foundation Trust.</p><p>Doncaster &amp; Bassetlaw Hospitals NHS Foundation Trust.</p><p>Mid Cheshire Hospitals NHS Foundation Trust.</p><p>North Cumbria University Hospitals NHS Trust.</p><p>Newcastle-Upon-Tyne Hospitals NHS Foundation Trust.</p><p>North Tees and Hartlepool NHS Foundation Trust.</p><p>Nottingham University Hospitals NHS Trust.</p><p>Poole Hospital NHS Foundation Trust.</p><p>Queen Elizabeth Queen Mother Hospital, Margate.</p><p>Royal Cornwall Hospitals NHS Trust.</p><p>Royal United Hospital Bath NHS Trust.</p><p>Royal Bournemouth &amp; Christchurch Hospitals NHS Trust.</p><p>South Tees Hospitals NHS Foundation Trust.</p><p>South Tyneside NHS Foundation Trust.</p><p>University Hospitals of Leicester NHS Trust.</p><p>Yeovil District Hospital NHS Foundation Trust.</p><p>York Hospitals NHS Foundation Trust.</p></sec><sec><title>Funding</title><p>Jointly and equally by the UK Alzheimer’s Society and UK Stroke Association.</p></sec></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Pendlebury</surname><given-names>ST</given-names></name><name><surname>Rothwell</surname><given-names>PM</given-names></name><article-title>Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis</article-title><source>Lancet Neurol</source><year>2009</year><volume>8</volume><issue>11</issue><fpage>1006</fpage><lpage>1018</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(09)70236-4</pub-id><pub-id pub-id-type="pmid">19782001</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Gottesman</surname><given-names>RF</given-names></name><name><surname>Hillis</surname><given-names>AE</given-names></name><article-title>Predictors and assessment of cognitive dysfunction resulting from ischemic stroke</article-title><source>Lancet Neurol</source><year>2010</year><volume>9</volume><issue>9</issue><fpage>895</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(10)70164-2</pub-id><pub-id pub-id-type="pmid">20723846</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Wiberg</surname><given-names>B</given-names></name><etal></etal><article-title>The relationship between executive dysfunction and post-stroke mortality: a population-based cohort study</article-title><source>BMJ Open</source><year>2012</year><volume>2</volume><issue>3</issue><fpage>eooo458</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2011-000458</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Melkas</surname><given-names>S</given-names></name><etal></etal><article-title>Depression-executive dysfunction syndrome relates to poor poststroke survival</article-title><source>Am J Geriatr Psychiatry</source><year>2010</year><volume>18</volume><issue>11</issue><fpage>1007</fpage><lpage>1016</lpage><pub-id pub-id-type="doi">10.1097/JGP.0b013e3181d695d7</pub-id><pub-id pub-id-type="pmid">20808085</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Nys</surname><given-names>GM</given-names></name><etal></etal><article-title>The prognostic value of domain-specific cognitive abilities in acute first-ever stroke</article-title><source>Neurology</source><year>2005</year><volume>64</volume><issue>5</issue><fpage>821</fpage><lpage>827</lpage><pub-id pub-id-type="doi">10.1212/01.WNL.0000152984.28420.5A</pub-id><pub-id pub-id-type="pmid">15753416</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Tham</surname><given-names>W</given-names></name><etal></etal><article-title>Progression of cognitive impairment after stroke: one year results from a longitudinal study of Singaporean stroke patients</article-title><source>J Neurol Sci</source><year>2002</year><volume>203–204</volume><fpage>49</fpage><lpage>52</lpage></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Pasquier</surname><given-names>F</given-names></name><name><surname>Henon</surname><given-names>H</given-names></name><name><surname>Leys</surname><given-names>D</given-names></name><article-title>Relevance of white matter changes to pre- and poststroke dementia</article-title><source>Ann N Y Acad Sci</source><year>2000</year><volume>903</volume><fpage>466</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2000.tb06400.x</pub-id><pub-id pub-id-type="pmid">10818539</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Stebbins</surname><given-names>GT</given-names></name><etal></etal><article-title>Gray matter atrophy in patients with ischemic stroke with cognitive impairment</article-title><source>Stroke</source><year>2008</year><volume>39</volume><issue>3</issue><fpage>785</fpage><lpage>793</lpage><pub-id pub-id-type="doi">10.1161/STROKEAHA.107.507392</pub-id><pub-id pub-id-type="pmid">18258824</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Collaborating</surname><given-names>PATS</given-names></name><article-title>Group: Post-stroke antihypertensive treatment study. A preliminary result</article-title><source>Chin Med J</source><year>1995</year><volume>108</volume><fpage>710</fpage><lpage>717</lpage><pub-id pub-id-type="pmid">8575241</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><collab>PROGRESS Collaborative Group</collab><article-title></article-title><source>Lancet</source><year>2001</year><volume>358</volume><fpage>1033</fpage><lpage>1041</lpage><pub-id pub-id-type="pmid">11589932</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Rashid</surname><given-names>PA</given-names></name><name><surname>Leonardi-Bee</surname><given-names>J</given-names></name><name><surname>Bath</surname><given-names>PM</given-names></name><article-title>Lowering blood pressure after stroke or transient ischemic attack to prevent recurrence: a systematic review of randomized controlled trials</article-title><source>Cerebrovasc Dis</source><year>2002</year><volume>13</volume><issue>suppl 3</issue><fpage>92</fpage><comment>abstract</comment></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Skoog</surname><given-names>I</given-names></name><etal></etal><article-title>15-year longitudinal study of blood pressure and dementia</article-title><source>Lancet</source><year>1996</year><volume>347</volume><issue>9009</issue><fpage>1141</fpage><lpage>1145</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(96)90608-X</pub-id><pub-id pub-id-type="pmid">8609748</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Petrovitch</surname><given-names>H</given-names></name><etal></etal><article-title>Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia aging Study</article-title><source>Neurobiol Aging</source><year>2000</year><volume>21</volume><issue>1</issue><fpage>57</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/S0197-4580(00)00106-8</pub-id><pub-id pub-id-type="pmid">10794849</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Launer</surname><given-names>LJ</given-names></name><etal></etal><article-title>Midlife blood pressure and dementia: the Honolulu-Asia aging study</article-title><source>Neurobiol Aging</source><year>2000</year><volume>21</volume><issue>1</issue><fpage>49</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/S0197-4580(00)00096-8</pub-id><pub-id pub-id-type="pmid">10794848</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Tzourio</surname><given-names>C</given-names></name><etal></etal><article-title>Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease</article-title><source>Arch Intern Med</source><year>2003</year><volume>163</volume><issue>9</issue><fpage>1069</fpage><lpage>1075</lpage><pub-id pub-id-type="pmid">12742805</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Diener</surname><given-names>H-C</given-names></name><etal></etal><article-title>Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study</article-title><source>Lancet Neurol</source><year>2008</year><volume>7</volume><issue>10</issue><fpage>875</fpage><lpage>884</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(08)70198-4</pub-id><pub-id pub-id-type="pmid">18757238</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Peters</surname><given-names>R</given-names></name><etal></etal><article-title>Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial</article-title><source>Lancet Neurol</source><year>2008</year><volume>7</volume><issue>8</issue><fpage>683</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(08)70143-1</pub-id><pub-id pub-id-type="pmid">18614402</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Forette</surname><given-names>F</given-names></name><etal></etal><article-title>Prevention of dementia in randomized double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial</article-title><source>Lancet</source><year>1998</year><volume>352</volume><fpage>1347</fpage><lpage>1351</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(98)03086-4</pub-id><pub-id pub-id-type="pmid">9802273</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Ankolekar</surname><given-names>S</given-names></name><etal></etal><article-title>Clinical trials for preventing post stroke cognitive impairment</article-title><source>J Neurol Sci</source><year>2010</year><volume>299</volume><issue>1–2</issue><fpage>168</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">20855090</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Hart</surname><given-names>RG</given-names></name><name><surname>McClure</surname><given-names>LA</given-names></name><name><surname>Szychowski</surname><given-names>JM</given-names></name><name><surname>Coffey</surname><given-names>CS</given-names></name><name><surname>Pearce</surname><given-names>LA</given-names></name><collab>SPS3 Investigators BO</collab><article-title>Effects of clopidogrel added to aspirin in patients with recent lacunar stroke</article-title><source>Engl J Med</source><year>2012</year><volume>376</volume><issue>9</issue><fpage>817</fpage><lpage>825</lpage></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Jacova</surname><given-names>C</given-names></name><etal></etal><article-title>Cognitive impairment in lacunar strokes: the SPS3 trial</article-title><source>Ann Neurol</source><year>2012</year><volume>72</volume><issue>3</issue><fpage>351</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1002/ana.23733</pub-id><pub-id pub-id-type="pmid">23034910</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Steiner</surname><given-names>S</given-names></name><etal></etal><article-title>Simvastatin blunts endotoxin-induced tissue factor in vivo</article-title><source>Circulation</source><year>2005</year><volume>111</volume><issue>14</issue><fpage>1841</fpage><lpage>1846</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000158665.27783.0C</pub-id><pub-id pub-id-type="pmid">15824212</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Ii</surname><given-names>M</given-names></name><name><surname>Losordo</surname><given-names>DW</given-names></name><article-title>Statins and the endothelium</article-title><source>Vascul Pharmacol</source><year>2007</year><volume>46</volume><issue>1</issue><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.vph.2006.06.012</pub-id><pub-id pub-id-type="pmid">16920035</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Snowdon</surname><given-names>DA</given-names></name><etal></etal><article-title>Brain infarction and the clinical expression of Alzheimer disease. The Nun Study</article-title><source>JAMA</source><year>1997</year><volume>277</volume><issue>10</issue><fpage>813</fpage><lpage>817</lpage><pub-id pub-id-type="doi">10.1001/jama.1997.03540340047031</pub-id><pub-id pub-id-type="pmid">9052711</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><collab>Heart Protection Study Collaborative Group</collab><article-title>Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions</article-title><source>Lancet</source><year>2004</year><volume>363</volume><issue>9411</issue><fpage>757</fpage><lpage>767</lpage><pub-id pub-id-type="pmid">15016485</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><collab>The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators</collab><article-title>High-dose atorvastatin after stroke or transient ischemic attack</article-title><source>Engl J Med</source><year>2006</year><volume>355</volume><issue>6</issue><fpage>549</fpage><lpage>559</lpage></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Manktelow</surname><given-names>BN</given-names></name><name><surname>Potter</surname><given-names>JF</given-names></name><article-title>Interventions in the management of serum lipids for preventing stroke recurrence</article-title><source>Cochrane Database Syst Rev</source><year>2009</year><volume>8</volume><issue>3</issue><comment>CD002091</comment></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><collab>HPS</collab><article-title>MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial</article-title><source>Lancet</source><year>2002</year><volume>360</volume><issue>9326</issue><fpage>7</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">12114036</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Shepherd</surname><given-names>J</given-names></name><etal></etal><article-title>Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial</article-title><source>Lancet</source><year>2002</year><volume>360</volume><issue>9346</issue><fpage>1623</fpage><lpage>1630</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(02)11600-X</pub-id><pub-id pub-id-type="pmid">12457784</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Golomb</surname><given-names>BA</given-names></name><name><surname>Evans</surname><given-names>MA</given-names></name><article-title>Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism</article-title><source>Am J Cardiovasc Drugs</source><year>2008</year><volume>8</volume><issue>6</issue><fpage>373</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.2165/0129784-200808060-00004</pub-id><pub-id pub-id-type="pmid">19159124</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Bamford</surname><given-names>J</given-names></name><etal></etal><article-title>Classification and natural history of clinically identifiable subtypes of cerebral infarction</article-title><source>Lancet</source><year>1991</year><volume>337</volume><fpage>1521</fpage><lpage>1526</lpage><pub-id pub-id-type="doi">10.1016/0140-6736(91)93206-O</pub-id><pub-id pub-id-type="pmid">1675378</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Adams</surname><given-names>HP</given-names></name><etal></etal><article-title>Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial</article-title><source>Stroke</source><year>1993</year><volume>24</volume><fpage>35</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1161/01.STR.24.1.35</pub-id><pub-id pub-id-type="pmid">7678184</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Lenzi</surname><given-names>GL</given-names></name><name><surname>Altieri</surname><given-names>M</given-names></name><article-title>Short-term evolution as a marker of vascular dementia versus Alzheimer's disease</article-title><source>J Neurol Sci</source><year>2007</year><volume>257</volume><issue>1–2</issue><fpage>182</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">17363000</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Jorm</surname><given-names>AF</given-names></name><name><surname>Jacomb</surname><given-names>PA</given-names></name><article-title>The informant questionnaire on cognitive decline in the elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms</article-title><source>Psycholog Med</source><year>1989</year><volume>19</volume><fpage>1015</fpage><lpage>1022</lpage><pub-id pub-id-type="doi">10.1017/S0033291700005742</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name><surname>Weir</surname><given-names>CJ</given-names></name><name><surname>Lees</surname><given-names>KR</given-names></name><article-title>Comparison of stratification and adaptive methods for treatment allocation in an acute stroke clinical trial</article-title><source>Stat Med</source><year>2003</year><volume>22</volume><fpage>705</fpage><lpage>726</lpage><pub-id pub-id-type="doi">10.1002/sim.1366</pub-id><pub-id pub-id-type="pmid">12587101</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><collab>Group, TGD</collab><article-title>Stroke: diagnosis and initial management of acute stroke and transient ischemic attack</article-title><source>NICE Clin Guidel</source><year>2008</year><volume>CG68</volume></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><collab>Group TGD</collab><article-title>Type 2 diabetes. The management of type 2 diabetes</article-title><source>NICE Clin Guidel</source><year>2009</year><volume>87</volume></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><name><surname>Amarenco</surname><given-names>P</given-names></name><etal></etal><article-title>High-dose atorvastatin after stroke or transient ischemic attack</article-title><source>N Engl J Med</source><year>2006</year><volume>355</volume><issue>6</issue><fpage>549</fpage><lpage>559</lpage><pub-id pub-id-type="pmid">16899775</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><name><surname>Cooper</surname><given-names>A</given-names></name><article-title>O'Flynn N, on behalf of the Guideline Development Group: Risk assessment and lipid modification for primary and secondary prevention of cardiovascular disease: summary of NICE guidance</article-title><source>BMJ</source><year>2008</year><volume>336</volume><fpage>1246</fpage><lpage>1248</lpage><pub-id pub-id-type="doi">10.1136/bmj.39554.624086.AD</pub-id><pub-id pub-id-type="pmid">18511800</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><collab>Group TGD</collab><article-title>Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolemia</article-title><source>NICE Technol Appr Guid</source><year>2007</year><volume>132</volume></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><name><surname>O'Brien</surname><given-names>E</given-names></name><name><surname>Atkins</surname><given-names>N</given-names></name><article-title>A comparison of the British Hypertension Society and Association for the Advancement of Medical Instrumentation protocols for validating blood pressure measuring devices: can the two be reconciled?</article-title><source>J Hypertens</source><year>1994</year><volume>12</volume><issue>9</issue><fpage>1089</fpage><lpage>1094</lpage><pub-id pub-id-type="pmid">7852754</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><name><surname>Dahlof</surname><given-names>B</given-names></name><etal></etal><article-title>Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicenter randomized controlled trial</article-title><source>Lancet</source><year>2005</year><volume>366</volume><issue>9489</issue><fpage>895</fpage><lpage>906</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(05)67185-1</pub-id><pub-id pub-id-type="pmid">16154016</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><collab>The Optimizing Analysis of Stroke Trials (OAST) Collaboration</collab><article-title>Can we improve the statistical analysis of stroke trials? Statistical re-analysis of functional outcomes in stroke trials</article-title><source>Stroke</source><year>2007</year><volume>38</volume><fpage>1911</fpage><lpage>1915</lpage><pub-id pub-id-type="pmid">17463316</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><collab>The Optimizing Analysis of Stroke Trials (OAST) Collaboration</collab><article-title>Calculation of sample size for stroke trials assessing functional outcome: comparison of binary and ordinal approaches</article-title><source>Int J Stroke</source><year>2008</year><volume>3</volume><fpage>78</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">18705999</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><collab>The Optimizing Analysis of Stroke Trials (OAST) Collaboration</collab><article-title>Should stroke trials adjust functional outcome for baseline prognostic factors?</article-title><source>Stroke</source><year>2009</year><volume>40</volume><fpage>888</fpage><lpage>894</lpage><pub-id pub-id-type="pmid">19164798</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><name><surname>Bowie CR</surname><given-names>HP</given-names></name><article-title>Administration and interpretation of the Trail Making Test</article-title><source>Nat Proc</source><year>2006</year><volume>1</volume><issue>5</issue><fpage>2277</fpage><lpage>2281</lpage></mixed-citation></ref></ref-list></back></article>